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Cancer: a heterogeneous disease 
In 2007 an estimated 7.9 million people across the world died from cancer, making 
it the leading cause of disease-related death worldwide1 (www.who.int/cancer). The 
highest incidence of new cancers can be ascribed to breast (women), prostate 
(men), colon and colorectal, lung and stomach cancers. It is estimated that the 
global cancer burden worldwide will continue to rise, with a projected 27 million 
new cases and 17.5 million deaths in 20502. 
In the Netherlands almost 90000 new cancer cases were reported in 2008, an 
increase of 30% compared with 1998 (www.ikcnet.nl). The number of reported 
deaths also increased and now accounts for 30% (40000 in 2008) of all mortality. 
Highest numbers of mortality were observed for carcinomas of the lung, colon, 
breast and prostate3,4. 
The standard treatment options available for cancer include surgery, chemotherapy 
and radiotherapy. Additional treatments can be given for certain cancer types like 
hormone therapy for breast cancer or immunotherapy for melanoma. Although 
advances in cancer research have improved prognosis by optimizing administration 
methods, combining standard therapeutic modalities and developing new drugs, a 
large fraction of patients do not benefit. Even patients with the same type of cancer 
have highly variable outcome and survival. 
This large variance can be attributed to the fact that cancer is a very heterogeneous 
disease, it comprises more than 100 distinct types that share a series of common 
phenotype characteristics that distinguish them from normal cells5. Although a 
series of processes affected during tumorigenesis, like proliferative capacity and 
growth factor dependency, are similar across patients, the way these characteristics 
are acquired can be very different5. Further, during tumor progression cells can 
acquire additional properties, for instance increased motility that can initiate 
invasion and metastasis formation, contributing to tumor aggressiveness6. A large 
number of genes and pathways are involved in these processes and therefore 
multiple gene mutations are needed for cancer to arise7. Recent genome 
sequencing studies have shown that each tumor has a unique mutational profile, 
with only a few mutations common to many cancers8-10. 
Another important aspect of tumor biology that might explain differences in 
treatment response is the tumor micro-environment6. Changes in the physiology of 
cancer cells lead to fluctuations in nutrient supply, pH, interstitial pressure and 
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tissue oxygenation that are uncommon for normal tissues11-15. Some of these 
unique features have previously been linked to treatment efficacy11,14-16. The 
chaotic and immature organization of tumor blood vessels impairs tumor 
oxygenation resulting in temporal and regional oxygen fluctuations. Certain tumor 
areas will be exposed to (severely) reduced oxygen levels, called hypoxia, which is 
associated with decreased treatment efficacy and enhanced aggressiveness16,17.   
Different combinations of mutations and tumor micro-environment give rise to the 
diverse behavior seen even amongst similar cancer types which is reflected in the 
highly variable treatment outcome and survival. This elucidates the need for more 
individualized therapy that takes into account specific genetic and micro-
environment tumor properties rather than a one-size fits all strategy. 
This leads directly to two pressing challenges in cancer biology. First, how should we 
select the most appropriate therapy for a specific patient? If molecular markers can 
be found that predict treatment outcome, these can be used to determine which 
currently available therapies will be most appropriate. Second how can new targets 
to create specific drugs for be identified? For example, if a single pathway is 
affected in poor outcome patients in a variety of different ways, then a drug 
targeting that pathway as a whole could be helpful. In the last decade, gene 
expression microarray technology has been applied to address these challenges. 
High-throughput Gene Expression Profiling 
Briefly, an expression microarray consists of a large panel of probes, representing 
thousands of genes that are immobilized to a solid matter. Labeled target (RNA, 
cRNA or cDNA) is subsequently hybridized to these probes and expression levels of 
each gene present on the microarray can be calculated. A snapshot of the whole 
transcriptome can thus be assessed in a single experiment. 
The ability to analyze the expression of thousands of genes created the opportunity 
to identify dysregulated pathways and find prognostic and predictive makers. 
Numerous prognostic gene expression-based markers, or so-called signatures, have 
been reported since the introduction of this high-throughput technology18-33. 
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Figure 1.1 
Schematic overview of patient data-derived gene-expression signature development. In step 
1 gene-expression profiling is performed on distinct (predefined) patient groups to extract 
genes differentially expressed between the patient groups. These genes are then used as 
signature and tested in independent patient data for their prognostic and/or predictive 
power (step 2). 
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Patient data-based signatures 
The most common approach has been to employ gene expression profiling on 
(large) series of tumor samples. Algorithms combining expression data with clinical 
parameters and/or survival data are then applied to create gene sets that can 
identify biologically and prognostically distinct tumor subgroups (Figure 1.1). In 
breast and non-small cell lung cancer a whole series of gene expression-based 
markers have been developed since the introduction of this 
technique18,21,23,27,28,32,33. 
The majority of markers are created by comparing gene expression in two patient 
categories; usually patients who relapse versus patients who do not. In breast 
cancer the number of created signatures is most extensive. 
Using this supervised top-down approach the 70-gene signature was developed 
from a retrospective series of 78 node-negative breast cancer patients who had 
received no systemic adjuvant therapy21. This marker was validated in a breast 
tumor series that included both node-positive and node-negative patients34. 
However since a large subgroup of these patients had received adjuvant systemic 
treatment and most of the patients in the original study were included in this 
second series, the results could have been biased. An independent study including 
more than 300 patients, who did not receive adjuvant systemic therapy, confirmed 
amongst others the prognostic power of the signature35-37. A customized microarray 
chip (MammaPrint, Agendia) to evaluate the 70-gene signature was recently cleared 
by the Food and Drug Administration (FDA) to aid in the prognostication of young 
early-stage node-negative breast cancer patients. The MINDACT trial, a large stage 
III clinical trial, is ongoing at the moment to confirm the classifier’s prognostic 
power and address its possible predictive value to select patients for systemic 
adjuvant therapy38,39. 
The 21-gene assay (OncoType DX, Genomic Health Inc.) is another gene expression-
based marker currently tested in a large stage III clinical trial; the TAILORx trial40. 
This quantitative PCR-based assay was developed for ER-positive breast cancers and 
can be applied to formalin-fixed paraffin-embedded (FFPE) material23. First, 250 
candidate genes were selected from published literature, which were subsequently 
profiled with PCR in 3 independent clinical studies comprising more than 400 
patients. A 21-gene panel was selected based on its correlation with the likelihood 
of distant recurrence and was used to develop an algorithm that computes a 
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recurrence score23. The 21-gene assay was further validated in multiple studies and 
a potential predictive capacity was demonstrated41-43. 
Perou et al18 applied another approach to identify distinct groups of breast cancers. 
A series of breast tissues, both normal and malignant, was profiled and diversity in 
gene expression patterns was related to phenotypic variation in breast tumors. This 
led to the definition of ‘the intrinsic gene list’; a subset of genes that groups breast 
tumors into distinct molecular subtypes. In a larger follow-up study the subtype 
classification was extended and differences in survival properties of the different 
subtypes were revealed44. In several consecutive studies the subtypes were further 
refined and their prognostic implications confirmed45-47. 
Biology-based signatures 
On the other hand gene expression signatures can be identified based on gene sets 
involved in a certain biological process or implicated in specific environmental 
conditions. Usually in vitro experiments are performed to create these biology-
based gene expression markers. Application of these markers to patient data could 
potentially be used to identify different prognostic groups and assess tumor 
sensitivity to a specific drug and predict therapy resistance (Figure 1.2). 
Several of these biology-based signatures show prognostic power across different 
cancer types22,26,31,48-52. One of the earliest examples is the Wound signature22. 
Similarities between wound healing and tumor microenvironment53,54 allowed 
researchers to the question whether identification of an activated wound response 
program in cancer could have prognostic implications. An in vitro cell culture model 
for wound healing55 was combined with gene expression microarray profiling to 
create a marker to classify wound response. In short, fibroblasts cultured from 
different anatomical sites where either cultured in normal media (10% fetal bovine 
serum (FBS)) or in low-serum media, containing only 0.1% FBS. Genes were selected 
based on their differential expression between the two conditions. To improve the 
specificity of their wound response signature, genes directly related to cell 
proliferation were eliminated from the gene list, leaving the 512 Core Serum 
Response (CSR) genes. The CSR genes, referred to as the Wound signature, 
identified subgroups of cancer patients with an activated wound response that 
correlated with worse survival in breast, lung and gastric cancer22. This prognostic 
power was validated in multiple studies56,57. 
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Figure 1.2 
Schematic overview of biology-derived gene-expression signature development. In step 1 
gene-expression profiling is performed on cells grown under distinct culture conditions in 
vitro to identify differentially expressed genes between the conditions. These genes are then 
used as signature and tested in patient data to address whether they have prognostic and/or 
predictive power (step 2). 
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A microenvironmental feature studied extensively at the gene expression level is 
hypoxia31,50-52. Series of hypoxia signatures have been created, but only a few were 
validated in follow-up studies. One of these is the hypoxia metagene31, which was 
derived from a set of well-characterized hypoxia-related genes from which ‘seed’-
genes were used to identify co-expressed genes in patient data. This larger gene-
set, the hypoxia metagene, is subsequently used to subgroup patients with the idea 
that patients with a high hypoxia metagene score have worse survival. The 
methodology was refined and validated in follow-up studies58,59. 
Challenges in microarray gene expression profiling 
Although a large number of patient data-based signatures have been created for 
specific cancer types and generated from a similar starting point, the overlap 
between such signatures is extremely small27,28,60,61. The initially reported classifier 
performance is often very strong, but validation in other datasets often fails60,62,63. 
This reflects both the significant technical challenges involved in introducing 
microarrays into a clinical setting, and over-fitting caused by large numbers of genes 
and relatively small patient cohorts. Taken together, these data also help to explain 
why only a few markers are currently being tested in large prospective trials. 
To make them clinically useful, variability across a large number of parameters has 
to be taken into account for any gene expression microarray analysis. This variability 
arises from the biological samples, hybridization protocols, scanning and analysis 
methods60,64. Differences in the use of these parameters are thus likely to cause 
discrepancies between signatures. Indeed poor inter-platform correlations have 
been reported65,66 and the use of different statistical procedures in one dataset 
could identify multiple highly prognostic signatures33. Since there are multiple 
microarray platforms, dozens of microarray pre-processing methods and numerous 
statistical and bioinformatics approaches to create gene expression signatures, 
standardization is challenging to achieve. 
In addition, the number of monitored genes (usually tens of thousands) in gene 
expression microarrays is large and the number of samples is relatively small. This 
makes multiple testing a serious issue in this type of research60,67. Without multiple 
testing correction the danger exists that false prognostics are identified. 
Corresponding to this, several studies have shown that signature performance can 
be overestimated62,67,68. Inherent to the data dimensionality issue, modeling studies 
have demonstrated that larger sample sizes would result in more robust results69,70. 
General introduction 
 
15 
Despite these hurdles, other methods to compare different gene expression 
markers show consistency, not in gene-wise overlap, but in prognostic performance. 
Comparison of a range of signatures in both breast and non-small-cell lung cancer 
revealed that signatures show significant agreement in the identified prognostic 
groups61,71,72. These data suggest that although signatures disagree in gene content, 
they track common underlying biology that determine patient outcome. Substantial 
data indicate that a major contributor to the prognostic power of signatures is 
proliferation71,73-75. It has been shown that a high number of published signatures 
contain a proliferation cluster of genes72,73. In a subset of these signatures 
prognostic performance even improved when only the proliferation genes were 
taken to classify patients72. 
Hypothesis and outline of this thesis 
As outlined in the previous paragraphs proliferation is one of the major biological 
processes implicated in the prognostic power of successful signatures. We 
hypothesized that a pure proliferation signature would have high prognostic power 
across a range of cancer types and could add value to current clinical practice. 
Chapter 2 describes a proliferation signature created from in vitro derived gene 
expression microarray data. This proliferation signature was able to identify groups 
of patients with poor survival in different datasets spanning several cancer types. 
We further related expression of the proliferation signature to mitotic index, 
another proliferation measure, in one of the studied datasets. 
Correlating gene expression signatures to biological processes measured with 
immunohistochemistry (IHC), could serve as a validation step to link biology-driven 
signatures with other measures of the process they allegedly track and might 
potentially elucidate the processes driving a patient data-based signature. We 
propose an in vivo based methodology to address these issues in chapter 3. In this 
in vivo based model we once more related expression of the proliferation signature 
to a measure of proliferation. 
To investigate the clinical applicability of the proliferation signature, we reduced the 
number of genes in the signature in order to evaluate it with PCR rather than 
microarrays. In chapter 4 this refined proliferation signature was validated, first in 
two large patient microarray meta-datasets, and consecutively in vitro, in vivo and 
in an independent patient dataset with PCR. 
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The second part of this thesis relates to the high dimensionality of gene expression 
microarrays and the resulting data analysis issues. We hypothesize that the multiple 
testing issue is not only crucial in the signature creation phase, but in addition plays 
an important role in signature testing. Therefore, in chapter 5 the effect of random 
generated signatures on prognostic findings is tested in a series of datasets. The 
percentage of random markers reaching statistical significance reached dramatic 
levels, but varied widely dependent on the dataset. We propose a simple method to 
test the likelihood that a signature performs better than chance. 
A recent review on gene expression-based classifiers in non-small-cell lung cancer63 
judged that published markers so-far had serious problems in their design and 
analyses, rendering them immature for clinical applicability. Several microarray 
studies were scored on the basis of a predefined set of criteria for study design, 
reporting and analyses. Each study either passed or failed a criterion, which is a 
rather black and white evaluation. For example a study providing three out of four 
specified clinical variables failed that criterion similar to a study that provided no 
covariates. In addition a couple of gene expression-based markers were tested in a 
new independent patient dataset. Data pre-processing as described in the original 
studies was not followed and the classifiers did not validate. In chapter 6 we argue 
that results in this review are not totally presented in a complete and accurate way 
leading to unnecessary harsh and biased conclusions. 
In chapter 7 we sought to determine the influence of microarray pre-processing 
methodology on signature performance. We hypothesized that differences in pre-
processing procedure could lead to erroneous conclusions regarding signature 
validation. A previously published gene expression classifier for non-small-cell lung 
cancer33 was tested in a large patient dataset32 pre-processed with 24 different 
schemes. Prognosticity was highly dependent on the preprocessing schedule used, 
emphasizing the importance of consistency in data analyses. Furthermore we 
validated two previously published non-small-cell lung cancer markers27,33 this new 
dataset. 
In conclusion, we created a highly prognostic gene expression-based marker for 
proliferation. This marker was successfully translated to a PCR-based classifier, 
which will increase clinical applicability. We further developed and validated two 
novel methods for assessing the robustness of gene expression-based biomarkers. 
Taking these into account will improve reported classifier validity and lead to a 
faster translation to a clinical setting. 
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Abstract 
Tumour proliferation is one of the main biological phenotypes limiting cure in 
oncology. Extensive research is being performed to unravel the key-players in this 
process. To exploit the potential of published gene expression data, creation of a 
signature for proliferation can provide valuable information on tumour status, 
prognosis and prediction. This will help individualizing treatment and should result 
in better tumour control, and more rapid and cost-effective research and 
development. 
From in vitro published microarray studies, two proliferation signatures were 
compiled. The prognostic value of these signatures was tested in five large clinical 
microarray datasets. More than 1,000 patients with breast, renal or lung cancer 
were included. One of the signatures (110 genes) had significant prognostic value in 
all datasets. Stratifying patients in groups resulted in a clear difference in survival 
(p-values < 0.05). Multivariate Cox-regression analyses showed that this signature 
added substantial value to clinical factors used for prognosis. Further patient 
stratification was compared to patient stratification with several well-known 
published signatures. Contingency tables and Cramer’s V statistics indicated that 
these primarily identify the same patients as the proliferation signature does. 
The proliferation signature is a strong prognostic factor, with the potential to be 
converted into a predictive test. Further, evidence is provided that supports the 
idea that many published signatures track the same biological processes and that 
proliferation is one of them. 
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Introduction 
The ability to predict outcome and to identify key-players in biological mechanisms 
that lead to poor outcome, are two important objectives in cancer research. 
Recently, efforts to exploit gene expression profiling have been made to identify 
gene sets, or so-called gene signatures, that can improve diagnosis and risk 
stratification1. A drawback of most of the studies performed is that supervised 
analysis methods are utilized to acquire such signatures. In this approach, patient 
microarray and clinical data are used to find gene sets that correlate with tumour 
type or survival. This often results in gene sets with a very high prognostic value in 
the studied dataset. However, comparative testing of these signatures in other 
patient datasets has been limited, and the overlap in selected genes of different 
comparable studies is small2. If such a signature can be applied to other datasets it 
may well be restricted to a certain patient population and cancer type. In addition, 
the gene sets obtained with this method are often difficult to interpret with respect 
to the underlying biological mechanism3,4. Further Dupuy and Simon5, showed in a 
recent review that many of these studies show flaws in methodology. 
An alternative approach to identify prognostic signatures is based on defining gene 
sets involved in a biological process or specific environmental condition that is 
suspected of influencing treatment response or patient outcome. In this approach, 
in vitro gene expression profiling is used to identify gene sets that play an important 
role in a specific biological process. The identified gene set is then applied to gene 
expression data from patients to evaluate its prognostic value. This approach has a 
more broad application because the gene sets can be applied in almost every 
patient group. Furthermore, it can be used not only to investigate whether a certain 
process is important in a distinct cancer type or patient group but also potentially to 
select patients in those groups that would be expected to benefit from therapies 
directed to the biological process of interest1. Examples of gene sets attained with 
this approach are the wound6, hypoxia7-9 and “invasiveness” (IGS)10 signatures. 
These studies show that the deduced signatures can be used for risk stratification in 
very different types of cancers6,7,9,10, presumably because of common core 
pathways that are influencing outcome in these diverse clinical groups. Another 
potential benefit of this unsupervised approach is that it can potentially identify the 
functional regulators within a signature that drive the studied process11 and thus 
reveal new targeting candidates. Recently Fan et al12, compared the performance of 
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several supervised and unsupervised derived gene sets and found that both types of 
signatures showed high concordance in prognostic power13. 
One of the biological processes often implicated in gene expression signatures is cell 
proliferation. The rate of tumour cell proliferation is a major contributor to 
treatment response with both chemotherapy and radiotherapy14 and is reflected in 
the fact that overall treatment time (e.g. duration of radiotherapy) is an important 
contributor to outcome15. In a recent review Whitfield et al16, showed that 
proliferation may underlie the prognostic power of many previously identified 
signatures. He showed that in almost every supervised derived signature a large 
subset of genes involved in proliferation is included3,17,18. In some cases, these 
classifiers have even been designated as ‘proliferation’ signatures although there 
derivation was not based on this phenotype. Two of these signatures have recently 
made it to the clinical setting as a diagnostic tool for patients with breast cancer19,20. 
Based on these results, we hypothesized that derivation of a specific in vitro derived 
signature based solely on proliferation may provide valuable information on tumour 
status, prognosis and outcome prediction across diverse tumour types. 
Materials and methods 
Datasets 
Patient microarray and clinical follow-up data were collated to test the clinical value 
of the signatures. Datasets are publicly available in the microarray databases Gene 
Expression Omnibus (GEO) and Stanford Microarray Database (SMD) or elsewhere. 
Accessory clinical and follow-up data were also given or provided by the authors on 
request. In Table 2.1 an overview of the datasets and where they are accessible is 
provided. Data filtering and pre-processing is explained in the supplementary data 
(Supplementary materials and methods). Datasets were imported in Matlab (Matlab 
7.1, The Mathworks, Massachusetts, USA). Unless indicated otherwise, analyses 
were performed in this program. 
Signature score calculation 
Expression data of the genes in the signature was extracted from the dataset. The 
following step was used to calculate a signature score for each patient in the 
dataset. This score was defined as the weighted average expression value of the 
genes in the signature (Equation 1). A weight of -1 or 1 was assigned to each gene, 
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dependent on the phenotype the gene represented. Weight assignment is 
described in the results and supplementary data (Supplementary materials and 
methods). 
The signature score then reflects the status of the studied process in a tumour. 
When a gene was represented by more than one probe on an array, the expression 
of the probes was averaged before signature calculation. 
N
exp  w
  Score
N
1i
ii
=
⋅
=       Equation (1) 
With: Score = signature score 
 N = number of genes in the signature 
 i = gene 
 wi = weight of gene i 
 expi = gene expression of gene i 
Statistical analysis 
A loop of 1,000 clustering repeats with the K-means clustering function in Matlab 
was applied to split the patients in two groups according to their signature score. 
Outcome in the two groups was analyzed and compared by the Kaplan-Meier 
method. Differences in outcome were tested for statistical significance by the log-
rank test for different common end-points. For breast and renal cancer the common 
end-points are 5-years and 10-years survival, for lung cancer these are 2-years and 
5-years survival, all end-points were analyzed when follow-up was long enough. 
Results for the log-rank tests are given as the average, standard deviation and the 
range of the p-values, also the percentage of p-values from the 1,000 clustering 
runs that were significant was calculated to evaluate the prognostic power of the 
signature and stability of the clustering. 
Multivariate Cox regression analysis with stepwise backward selection procedure 
was performed in SPSS (SPSS 12.0.1, SPSS Inc, Illinois, USA) to show the clinical 
relevance of the proliferation signature. 
AUC model calculation 
Matlab was used to integrate all parameters in a model with and without addition 
of the signature to the clinical parameters. Differences between the models were 
assessed using receiver operator curve (ROC) analysis by calculating the AUC. 
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Further details are provided in the supplementary data (Supplementary materials 
and methods). 
Random signature testing 
A method to test a predefined number of random signatures of a predefined size on 
all the datasets was developed. To show the strength of a signature 10,000 random 
generated gene sets, with sizes equal to the size of the signature of interest, were 
tested on the datasets. These random gene sets were tested in a similar manner as 
the other signatures. 
Mitotic index scoring 
MI was assessed (as part of histological grading) in the 295 breast tumours of the 
van de Vijver dataset13 using a microscope with a field diameter of 0.44 mm using a 
x40 objective. The area with the highest mitotic activity was selected and mitotic 
figures were counted in 10 consecutive fields. Tumours were assigned to the 
following groups based on the mitotic counts: 
- Group 1: 0-5 mitoses in 10 high power fields  
- Group 2: 6 -10 mitoses in 10 high power fields 
- Group 3: ≥ 11 mitoses in 10 high power fields 
 
Table 2.1 A Overview of the analyzed patient microarray datasets, B: Number of signature genes 
represented in the microarray dataset (number of gene identifiers on the arrays are given between 
brackets). 
A     
Dataset Cancer site # patients Source 
Miller Breast 251 GEO accession GSE3494: 
http://www.ncbi.nlm.nih.gov/projects/geo/ 
Wang Breast 286 GEO accession GSE2034: 
http://www.ncbi.nlm.nih.gov/projects/geo/ 
van de Vijver Breast 295 http://microarray-pubs.stanford.edu/wound_NKI/ 
Zhao Renal 177 SMD: http://smd.stanford.edu/ 
Beer Lung 86 http://dot.ped.med.umich.edu:2000/ourimage/pub
/Lung/index.html 
B      
Dataset Signature 1 Signature 2 Wound signature IGS signature 
Miller 455 (1120) 104 (228) 415 (1030) 176 (516) 
Wang 350 (667) 87 (158) 346 (614) 131 (270) 
van de Vijver 192 (242) 51 (59) 171 (195) 67 (87) 
Zhao 257 (415) 47 (82) 280 (446) 83 (132) 
Beer 192 (224) 45 (51) 171 (195) 63 (76) 
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Results 
Signature derivation 
From published microarray studies two different proliferation signatures were 
compiled. Whitfield et al21, studied the cell cycle in HeLa cells (cervix cancer cell 
line). Microarrays were performed on synchronized cell cultures at different time-
points and genes that showed a periodic variation were selected. These genes were 
grouped according to the cell cycle phase in which their expression peaked. We 
propose that this gene set could be employed as a specific proliferation signature. 
Another method to derive a proliferation signature with microarrays was employed 
by Chang et al6. Human fibroblasts were serum starved for 48 hours and then 
stimulated with serum to simulate a wound response. One of the most consistent 
and important effects in the serum response program is stimulation of proliferation. 
Abnormal proliferation is also a consistent characteristic of cancer cells, irrespective 
of a wound response6. Chang et al6, therefore discarded the genes with a periodic 
behavior to specifically study the wound response. Here we propose that the set of 
genes discarded from the wound signature is a good representation of a 
proliferation signature. This signature is a subset of the signature derived from 
Whitfield et al21, however we postulate that it is a better representative of 
proliferation and will be a better prognostic factor, since only this gene set shows a 
change in expression upon serum stimulation. 
The wound6 and IGS10 signature are two promising published unsupervised derived 
signatures. Further the second proliferation signature is derived from the same in 
vitro data as the wound signature. Therefore these signatures were also analyzed. 
Comparison of two proliferation signatures 
Signature 121 and signature 26 consist of respectively 1,134 and 199 cloneIDs that 
map to 815 and 154 unique UnigeneIDs, respectively. The distribution of genes in 
the different cell cycle phases for the two signatures is distinct (Supplementary data 
Table S2.1), indicating that the signatures are different. Signature 1 shows equal 
proportions of genes in the defined cell cycle phases. However in signature 2 more 
genes are involved in G2 and clearly less genes are involved in M/G1. 
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Outcome prediction with proliferation signatures 
The signatures were tested for their clinical relevance on several publicly available 
microarray datasets (Table 2.1). Signatures were evaluated using a signature score 
(Equation 1), which is defined as a weighted average of the expression of the genes 
in the signature. To calculate the signature score, weights were defined for each 
gene. After translating the signatures into UnigeneIDs (build199) and weight 
assignment several genes were discarded from analyses, for these genes weight 
assignment was ambiguous, details are provided in the supplementary materials 
and methods. The final signatures consist of respectively 508 and 110 UnigeneIDs 
for signature 1 and 2. 
In every dataset a signature score (Equation 1) was calculated for each patient. The 
patients were separated in two groups by clustering these signature scores, to 
obtain a natural separation rather than using an arbitrary value like the median to 
split the patients. This clustering was repeated 1,000 times to assess the stability of 
the group assignment. Results of the log-rank tests are given in supplementary data 
Table S2.2 and in Figure 2.1 the Kaplan-Meier curves for signature 2 are shown. 
Signature 2 gives clear risk stratification in all datasets, all p-values of the 1,000 
clustering runs < 0.05. Results of the log-rank test show not only that signature 2 
gives a better risk stratification than signature 1, also the overall robustness of the 
separation is stronger, indicated by the small standard deviations. Nevertheless 
both signatures show very good prognostic value on the three breast cancer 
datasets. The range and standard deviations of the 1,000 clustering runs also show 
that the results are robust for these datasets and that splitting patients based on 
clustering of signature scores is stable. 
Statistical analysis of signature scores 
Multivariate Cox-regression analyses were performed to investigate whether the 
association between the best proliferation signature and outcome was independent 
of clinical prognostic factors. The variables analyzed differed per dataset, since 
different clinical factors are provided (Supplementary data Table S2.3). A stepwise 
backward selection procedure was performed to select the variables that are 
prognostic factors; the end-point is 10-years for breast and renal cancer and 5-years 
for lung cancer. Follow-up time in the Wang et al22 dataset is not long enough, in 
that dataset 5-years was used. In Table 2.2 the factors selected with this procedure 
are given for all the datasets, choosing another end-point did not influence the 
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results dramatically (Supplementary data Table S2.4). In 4 out of 5 datasets the 
proliferation signature is included in the model as a prognostic factor of outcome. In 
3 datasets this was highly significant and in the fourth it reached border 
significance. 
 
Figure 2.1 
 A signature score was calculated for each patient in the different datasets. These scores 
were used to cluster the patients in two groups, one with low expression and one with high 
expression of the signature. Kaplan-Meier survival curves for the two groups were compared 
(A: Miller dataset, B: Wang dataset, C: van de Vijver dataset, D: Zhao dataset, E: Beer 
dataset). 
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Table 2.2 Clinical parameters selected with stepwise backward selection in multivariate Cox-regression 
analyses including signature 2. 
Miller Hazard ratio (95% CI) p-value 
Tumor size 3.3 (1.7 - 6.6) 0.0006 
LNS† 2.8 (1.6 - 5.0) 0.0003 
Proliferation** 3.4 (1.4 - 8.2) 0.0052 
Wang Hazard ratio (95% CI) p-value 
Proliferation** 2.6 (1.5 - 4.4) 0.0004 
van de Vijver Hazard ratio (95% CI) p-value 
Age 0.95 (0.91 - 0.99) 0.0096 
Tumor size* 1.5 (0.93 - 2.5) 0.0962 
Elston grade 2.2 (1.4 - 3.4) 0.0003 
Proliferation** 21 (1.8 - 234 ) 0.0148 
Zhao Hazard ratio (95% CI) p-value 
Performance status 1.3 (1.1 - 1.6) 0.0069 
Grade 1.5 (1.0 - 2.1) 0.0260 
Stage 3.3 (2.5 - 4.4) < 0.0001 
Beer Hazard ratio (95% CI) p-value 
Age 1.0 (1.0 - 1.1) 0.0338 
Stage 2.3 (1.5 - 3.5) 0.0002 
Proliferation** 1.8 (0.9 - 3.5) 0.0884 
*    Categories: ≤ 2 cm or > 2 cm 
†    LNS: lymph-node status 
** Proliferation: proliferation signature 2 
AUC calculations 
The area under the receiver-operator curve (AUC) was calculated for each clinical 
parameter and the best proliferation signature. Results of this analyses show that 
the proliferation signature has a high AUC compared to the clinical parameters in all 
datasets (Supplementary data Table S2.3). 
To quantify the gain in prognostic power obtained with this signature a model of 
the clinical factors with and without the signature was generated and evaluated 
with the AUC. Part of the dataset was used as training set, to generate the model, 
and the other part as a test set. Only the datasets with more than 1 clinical 
parameter and more than 150 patients are included. Different sizes of training and 
test sets were evaluated; the overall performance did not change significantly (data 
not shown). The results shown in Figure 2.2 were produced with 150 and 100 
samples as training set for the breast cancer and the renal cancer datasets 
respectively. In 2 out of 3 datasets the AUC increased significantly when the 
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proliferation signature was added to the model (Figure 2.2, p-values paired t-test « 
0.0001). 
 
Figure 2.2 
A model of the clinical factors with and without the signature was generated. Receiver 
operator curves (ROC) were used to compare the two models in three datasets. (A: Miller 
dataset, B: van de Vijver dataset, C: Zhao dataset). 
 
Random signature testing 
In order to show the strength of the proliferation signature, 10,000 random 
generated signatures were tested on all datasets. Of these 10,000 no signature gave 
a significant result on all datasets. 
Comparison to other signatures 
Log-rank tests and Kaplan-Meier survival curves show that the wound and IGS 
signature give clear risk stratification in 4 and 5 datasets respectively 
(Supplementary data Table S2.2). Further inclusion of these signatures in 
multivariate Cox-regression analyses (Supplementary data Table S2.4) gives the 
indication that combining signatures, like the proliferation and IGS signature in one 
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of the datasets can strengthen the prognostic power of microarray profiling in a 
clinical setting. Combining the proliferation and wound signature did not add value 
in any of the datasets. 
To investigate whether different signatures identify the same patients, two-way 
contingency table analyses (Supplementary materials and methods) were 
performed to compare the patient classification of the proliferation signature to the 
classification of other signatures. For the gene sets identified in three of the five 
datasets13,23,24, group classification was available (details are provided in the 
Supplementary materials and methods), these and the wound and IGS signature 
were evaluated. Contingency table analyses and Cramer’s V statistics 
(Supplementary data Tables S2.5-S2.9) show that the proliferation signature has a 
strong association with all other signatures evaluated, indicating that these 
signatures identify the same patients. 
Proliferation signature validation 
The proliferation signature is extracted from in vitro data, however this does not 
necessarily mean that the signature truly tracks proliferation in vivo. To investigate 
this mitotic index (MI) was assessed for the van de Vijver13 dataset, which was 
scored in three classes. In Figure 2.3 a boxplot is shown of the proliferation score 
versus the MI. There is a clear correlation between the average proliferation 
signature score and the three classes of MI (correlation coefficient: 0.968). 
 
 
Figure 2.3 
Correlation between the proliferation signature score and the mitotic index in the van de 
Vijver dataset. 
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Discussion 
We derived a proliferation signature from in vitro microarray studies based only on 
genes that differ in expression in different parts of the cell cycle6,21. Results show 
that the proliferation signature has a high value in patient risk stratification in five 
large clinical studies involving more than 1,000 patients and three different cancer 
sites. This contrasts with previous studies that rarely validate signatures in more 
than one large independent dataset.  
Our data indicate that the proliferation signature can be combined with other 
phenotype based signatures, to further improve patient stratification. The fact that 
large clusters of proliferation genes are identified in many gene signatures3,10,17,18,25-
27 raises the possibility that many of previously reported gene signatures, including 
the wound signature, may be highly influenced by proliferation. Fan et al12, has 
previously suggested that many signatures track a common set of biologic 
phenotypes and have therefore a similar prognostic strength. Whitfield et al16, has 
further suggested that one of these processes is proliferation. The performance of 
the proliferation signature in our study supports this idea. Comparisons of the 
proliferation signature to five other gene sets showed that these signatures 
primarily identify the same patients as the proliferation signature. 
Some reports refer to their signature as a proliferation signature3,27. However in 
these supervised studies not all genes in the signature are related to proliferation 
and therefore cannot be referred to strictly as general proliferation signatures. For 
example, Dai et al3, used a supervised approach to determine a signature associated 
with metastasis. Many of the identified genes were known to be involved in cell 
cycle regulation and these authors thus referred to their classifier as a proliferation 
signature. However only 17 out of 50 genes in this signature are cell cycle related 
when assessed in the initial gene list of Whitfield et al21. The same applies to the 
study of Rosenwald et al27, only 28 of the 48 genes that were associated with length 
of survival are related to proliferation. 
The proliferation signature has a high prognostic power, like many signatures, 
however it is one of the few signatures that may also have a predictive value. It can 
possibly be used to prescribe a treatment targeting tumour proliferation. Studies 
indicate that fast proliferating tumours can benefit from accelerated radiotherapy 
or chemo-radiotherapy28,29. The proliferation signature could possibly be used as 
basis for a predictive test for patient selection for these treatments. 
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Previous studies have tried to assess the predictive value of proliferation by means 
of MI, Ki67 staining and potential doubling time (Tpot) calculation. Overall results of 
these single-parameter indicators are disappointing30. MI and Ki67 staining are the 
most promising parameters; however results for these markers are controversial30-
33. This can be due to the large chance of misclassification with these single-
parameter indicators16,33. Application of multi-parameter indicators, like the 
proliferation signature, is therefore a more attractive method16. The proliferation 
signature shows a clear correlation with MI in one of the tested datasets. 
In conclusion we have shown that the application of phenotype based signatures 
like the proliferation signature can be used in patient risk stratification, in addition 
to clinical parameters. It has a high prognostic value and unlike other signatures it 
has the potential to be converted into a predictive test. Furthermore, we provide 
evidence that supports the idea that many published signatures track the same 
biological processes and that proliferation is one of them. Whether the proliferation 
signature can be converted into a predictive test should be evaluated in a large 
prospective trial in which other measures for proliferation should also be evaluated. 
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Supplementary material and methods 
Signature processing 
For all signatures the gene identifiers were translated into UnigeneIDs (Build199) 
with Source (http://smd.stanford.edu/) or Affymetrix data files 
(www.affymetrix.com: Affx annotation files). After this translation several genes in 
the proliferation signatures were represented by more than one cloneID. In case 
these cloneIDs represented the same proliferation status they were included in the 
signature. However when multiple cloneIDs representing one gene corresponded to 
different proliferation conditions these genes were discarded. This was 
approximately 3% of the genes in each signature. 
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Data filtering and pre-processing 
Datasets downloaded from the SMD34 were filtered according to the parameters in 
the paper. CloneIDs were chosen as gene annotation and the data obtained was log-
transformed. For the normalized affymetrix arrays22,24 the genes were log-
transformed. The Beer et al23 dataset was already preprocessed therefore to 
perform log-transformation all expression values below 1.1 were set to 1.1, this was 
similar to the processing performed by Chen et al2. In all other cases the data was 
kept in the downloaded format13, which was already log-transformed. CloneIDs and 
affymetrix probeIDs were translated into UnigeneIDs (Build199). 
Weight assignment 
Genes with a peak expression in S, G2 and M phase clearly are proliferation genes. 
Higher expression of these genes will correlate with a larger proportion of cells in S, 
G2 and M phase, which indicates more proliferation. That does not apply to genes 
with a peak expression in G1, since a G1 cell may or may not commit to cell cycle. 
Therefore genes with a peak expression in G1, 34% and 25% of the genes in 
signature 1 and 2 respectively, were omitted from further analyses. Equal weights 
were assigned to the remaining genes in the two proliferation signatures. 
For the wound signature weights of -1 and 1 were assigned to genes representing a 
quiescent and activated wound response respectively. For the IGS signature log 
ratios were provided in the supplementary data of the paper, a weight of 1 is 
assigned to genes with a positive log ratio and a weight of -1 to genes with a 
negative log ratio. 
AUC model calculation 
Matlab (Matlab 7.1, The Mathworks, Massachusetts, USA) was used to integrate all 
parameters in a model and evaluate the area under the curve (AUC) of the model 
with and without addition of the signature to the clinical parameters. All clinical 
parameters were transformed to numbers, to be able to incorporate them in 
Matlab, e.g. negative and positive ER-status were set to 0 and 1 respectively. These 
parameters were incorporated in a model with the classify function of Matlab, 
which used the diaglinear method. Part of the dataset was used as training set and 
the other part as a test set. Assignment of samples to test and training set was done 
at random and repeated 1,000 times. 
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Contingency table analyses 
Contingency tables were used to compare patient classification of the proliferation 
signature to the patient classification of other gene signatures. For three 
datasets13,23,24 we were able to find the group classification of the gene signatures 
identified in these studies: the 32-gene p53 signature24, the 70-gene signature13 and 
the 100 survival related genes23. These and the wound response and IGS signature 
were evaluated. 
Contingency tables were evaluated with the p-value calculated from Chi-square test 
and the Cramer’s V statistic. The Cramer’s V statistic (value can range from 0 to 1) 
measures the strength of association between the two variables analyzed in the 
contingency table, with 1 indicating perfect association and 0 indicating no 
association. Values between 0.36 and 0.49 indicate a substantial relation between 
the signatures and values >0.50 indicate a strong relation12. 
Supplementary tables 
 
Table S2.1 Percentages of genes in the different cell cycle phases in the two proliferation signatures 
(numbers are given between brackets). 
Cell cycle phase Signature 1 Signature 2 
G1/S 18.0 (147) 18.8 (29) 
S 18.0 (147) 19.5 (30) 
G2 19.5 (159) 26.0 (40) 
G2/M 21.7 (177) 22.1 (34) 
M/G1 16.0 (130) 6.5   (10) 
Matching combinations* 3.1   (25) 3.9   (6) 
Non-matching combinaƟons† 3.7   (30) 3.3   (5) 
* Different cloneIDs for 1 UnigeneID are found in different phases, but all phases represent the same 
proliferation status (i.e S, G2, G2/M) 
† Different cloneIDs for 1 UnigeneID are found in different phases and the phases represent a different 
proliferation status (i.e G2/M, G1/S) 
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Table S2.2 Results of log-rank test for the signatures for the different endpoints. 
Signature 1 
Dataset Endpoint P-value SD Range % significant runs 
Miller 5 years 3.1x10-3 1.6x10-3 1.5x10-3 - 4.7x10-3 100 
 10 years 6.9x10-4 3.4x10-4 3.6x10-4 - 1.0x10-3 100 
Wang 5 years 1.9x10-3 1.0x10-3 9.9x10-4 - 3.0x10-3 100 
van de Vijver 5 years 4.6x10-5 0.0 4.6x10-5 - 4.6x10-5 100 
 10 years 2.5x10-7 0.0 2.5x10-7 - 2.5x10-7 100 
Zhao 5 years 0.48 8.0x10-2 0.39 - 0.55 0 
 10 years 0.54 3.0x10-2 0.51 - 0.57 0 
Beer 2 years 0.16 5.4x10-2 0.12 - 0.20 0 
 5 years 0.49 9.8x10-2 0.11 - 0.63 0 
Signature 2 
Dataset Endpoint P-value SD Range % significant runs 
Miller 5 years 4.1x10-3 1.8x10-3 2.0x10-3 - 6.2x10-3 100 
 10 years 7.0x10-4 1.8x10-4 4.6x10-4 - 9.3x10-4 100 
Wang 5 years 2.3x10-3 1.8x10-4 5.7x10-5 - 6.4x10-4 100 
van de Vijver 5 years 1.4x10-6 0.0 1.4x10-6 - 1.4x10-6 100 
 10 years 3.0x10-8 1.6x10-10 3.0x10-8 - 3.0x10-8 100 
Zhao 5 years 3.1x10-2 1.1x10-2 1.9x10-2 - 4.2x10-2 100 
 10 years 2.3x10-2 3.2x10-3 2.0x10-2 - 2.7x10-2 100 
Beer 2 years 3.3x10-3 2.2x10-5 3.3x10-3 - 3.4x10-3 100 
 5 years 2.8x10-2 6.8x10-5 2.8x10-2 - 2.8x10-2 100 
Wound signature 
Dataset Endpoint P-value SD Range % significant runs 
Miller 5 years 1.8x10-4 1.1x10-4 4.8x10-5 - 8.7x10-4 100 
 10 years 9.3x10-6 3.9x10-6 3.1x10-6 - 3.9x10-5 100 
Wang 5 years 2.1x10-3 1.4x10-3 5.1x10-4 - 4.1x10-3 100 
van de Vijver 5 years 5.9x10-5 0.0 5.9x10-5 - 5.9x10-5 100 
 10 years 9.3x10-7 5.2x10-9 9.3x10-7 - 9.4x10-7 100 
Zhao 5 years 2.1x10-2 6.9x10-3 2.5x10-2 - 3.1x10-2 100 
 10 years 2.8x10-2 2.7x10-3 1.4x10-2 - 2.8x10-2 100 
Beer 2 years 6.9x10-2 5.1x10-2 1.5x10-2 - 0.10 49 
 5 years 0.12 1.2x10-2 8.1x10-2 - 0.13 0 
IGS signature 
Dataset Endpoint P-value SD Range % significant runs 
Miller 5 years 5.3x10-3 2.6x10-3 2.8x10-3 - 8.1x10-3 100 
 10 years 2.4x10-3 7.4x10-4 1.7x10-3 - 3.2x10-3 100 
Wang 5 years 2.1x10-6 1.7x10-6 4.3x10-7 - 5.1x10-6 100 
van de Vijver 5 years 1.5x10-4 0.0 1.5x10-4 - 1.5x10-4 100 
 10 years 4.9x10-7 0.0 4.9x10-7 - 4.9x10-7 100 
Zhao 5 years 2.2x10-3 1.0x10-3 1.0x10-3 - 3.4x10-3 100 
 10 years 4.7x10-3 9.5x10-4 3.3x10-3 - 5.9x10-3 100 
Beer 2 years 2.8x10-2 6.6x10-3 2.3x10-2 - 3.7x10-2 100 
 5 years 5.4x10-2 5.4x10-3 5.0x10-2 - 6.1x10-2 61 
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Table S2.3 AUCs of individual clinical parameters and proliferation signature 2. 
Miller Wang van de Vijver 
Age 0.48 ER-status 0.62 Age 0.42 
Elston grade  0.65 Proliferation** 0.59 Elston grade 0.72 
Tumor size* 0.71   Tumor size* 0.67 
ER-status 0.58   ER-status 0.41 
LNS‡ 0.70   LNS‡ 0.52 
PgR§ 0.54   NIH risk 0.66 
P53-status 0.57   Mastectomy 0.57 
Proliferation** 0.67   Chemotherapy 0.52 
    Hormone therapy 0.53 
    Proliferation* 0.72 
Zhao Beer  
Age 0.43 Age 0.60   
Sex 0.45 Sex 0.45   
Performance status 0.60 Smoking† 0.49   
Grade 0.64 Stage 0.66   
Stage 0.85 Differentiation 0.59   
Proliferation** 0.56 K-ras mutation 0.52   
  Proliferation** 0.64   
*   Categories: ≤ 2 cm or > 2 cm 
†   Categories: smoker or non-smoker 
‡   LNS: lymph-node status 
§   PgR: progesterone receptor status 
**  proliferation: proliferation signature 2 
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Table S2.5 Two-way contingency table analyses measuring the association between the proliferation 
signature and the wound (A), IGS (B) and 32-gene p53 signature (C) in the Miller dataset. 
Wound signature A 
Quiescent Activated 
Proliferation signature Low score 120 15 
 High score 19 82 
Statistics: Cramer’s V = 0.70, p-value < 0.001 
IGS signature B 
Low score High score 
Proliferation signature Low score 105 30 
 High score 19 82 
Statistics: Cramer’s V = 0.58, p-value < 0.001 
32-gene p53 signature C 
p53-wt like P53-mu like 
Proliferation signature Low score 125 43 
 High score 10 58 
Statistics: Cramer’s V = 0.55, p-value < 0.001 
 
Table S2.6 Two-way contingency table analyses measuring the association between the proliferation 
signature and the wound (A) and IGS (B) signature in the Wang dataset. 
Wound signature A 
Quiescent Activated 
Proliferation signature Low score 124 12 
 High score 60 90 
Statistics: Cramer’s V = 0.53 p-value < 0.001 
IGS signature B 
Low score High score 
Proliferation signature Low score 91 45 
 High score 27 123 
Statistics: Cramer’s V = 0.50, p-value < 0.001 
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Table S2.8 Two-way contingency table analyses measuring the association between the proliferation 
signature and the wound (A) and IGS (B) signature in the Zhao dataset. 
Wound signature A 
Quiescent Activated 
Proliferation signature Low score 84 11 
 High score 49 33 
Statistics: Cramer’s V = 0.33, p-value < 0.001 
IGS signature B 
Low score High score 
Proliferation signature Low score 77 18 
 High score 30 52 
Statistics: Cramer’s V = 0.45, p-value < 0.001 
 
Table S2.7 Two-way contingency table analyses measuring the association between the proliferation 
signature and the wound (A), IGS (B) and 70-gene (C) signature in the van de Vijver dataset. 
Wound signature A 
Quiescent Activated 
Proliferation signature Low score 150 10 
 High score 25 110 
Statistics: Cramer’s V = 0.76, p-value < 0.001 
IGS signature B 
Low score High score 
Proliferation signature Low score 114 46 
 High score 34 101 
Statistics: Cramer’s V = 0.46, p-value < 0.001 
70-gene signature C 
Poor profile Good profile 
Proliferation signature Low score 106 54 
 High score 9 126 
Statistics: Cramer’s V = 0.61, p-value < 0.001 
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Table S2.9 Two-way contingency table analyses measuring the association between the proliferation 
signature and the wound (A), IGS (B) and 100 survival related genes (C) in the Beer dataset. 
Wound signature A 
Quiescent Activated 
Proliferation signature Low score 42 3 
 High score 6 35 
Statistics: Cramer’s V = 0.78, p-value < 0.001 
IGS signature B 
Low score High score 
Proliferation signature Low score 39 6 
 High score 14 27 
Statistics: Cramer’s V = 0.54, p-value < 0.001 
100 survival related genes C 
Low risk High risk 
Proliferation signature Low score 33 12 
 High score 10 31 
Statistics: Cramer’s V = 0.50, p-value < 0.001 
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Abstract 
Purpose: To investigate the use of xenograft models in a novel gene signature 
validation method using gene expression microarrays. 
Material and methods: Gene expression profiles of ten human Head and Neck 
squamous cell carcinomas (HNSCCs) were obtained. Several published prognostic 
gene expression signatures were evaluated within this set. These consisted of 
different radiotherapy relevant signatures (i.e. for hypoxia, proliferation and 
‘stemness’). Signatures were correlated with various endpoints that have been 
determined in the ten different xenograft models. These include 
immunohistochemical measures for hypoxia and proliferation, volume doubling 
time (VDT) and local tumour control after fractionated irradiation or after single 
dose irradiation under clamp hypoxia. 
Results: We found several significant correlations between the published gene 
expression signatures and tumour parameters. Several signatures, like the 
proliferation and wound signature correlated with BrdU labelling index. Further a 
‘stemness’ related gene signature showed a strong negative correlation with 
hypoxic fraction. 
Conclusions: Simultaneous assessment of immunohistochemistry, in vivo tumour 
properties and gene expression profiling in a comprehensive set of xenograft 
models can be used to validate and potentially infer biological information about 
prognostic gene signatures. 
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Introduction 
Within oncology, we are challenged with the fact that tumours with similar 
characteristics (i.e. stage, grade and size) show striking differences in response to 
the same therapy. Understanding the underlying causes of these differences is 
crucial if we want to improve and individualize cancer treatment. Over the last few 
years, expression microarrays have been used to identify sets of genes, or so-called 
signatures that can improve diagnosis and risk stratification1,2. Often these 
signatures are derived directly from clinical samples using supervised analysis 
methods to create gene sets that can identify patient groups with distinct risk 
properties1. One of the drawbacks of this method is that these signatures are often 
difficult to interpret with respect to the underlying biological mechanisms that may 
be responsible for this categorization3,4. Conversion of these prognostic signatures 
into predictive tests is therefore not straightforward. An alternative approach 
utilizes in vitro expression profiling to identify gene sets that are responsive to a 
specific biological process. Several studies have identified signatures with this 
procedure which are associated with prognosis5-8. 
We hypothesize that a signature evaluation step in an animal model in vivo might 
provide novel insight for both of these methodologies. A signature can be evaluated 
in a set of tumour xenograft models, in which in parallel other relevant tumour 
features are assessed. Immunohistochemistry can be implemented to assess for 
example hypoxic fraction (HF) and proliferation. Furthermore, volume doubling 
time (VDT) and the radiation dose necessary to locally control 50% of the tumours 
(TCD50) are radiotherapy treatment relevant variables. Comparison of various 
signatures with these phenotypic parameters can potentially provide unique 
information into the underlying biological mechanisms that confer prognostic 
power to the signatures. This is especially true for signatures derived from clinical 
studies for which no a priori expectation of its biological basis is available. For an in 
vitro derived signature this can be used as an extra in vivo validation step. 
Proliferation, hypoxia and ‘stemness’ are parameters implicated in determining 
outcome of radiotherapy9-14. Gene signatures related to these phenotypes may thus 
provide valuable information on prognosis and prediction for patients treated with 
radiotherapy. Here we have explored the possibility of validating several of these 
published signatures related to these features on a comprehensive dataset of 
human tumour xenografts. 
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Materials and methods 
Animals and tumour models 
The experiments were performed using 7 to 14 week-old male and female NMRI-nu 
(nu/nu) mice (Experimental Centre of the Medical Faculty of the University of 
Dresden). Animal facilities and experiments were approved according to the 
German animal welfare regulations. Ten human head and neck squamous cell 
carcinomas (HNSCC) were used. These have been described in detail previously see 
Table 3.112,15-17. For the experiments, source tumours were cut into small pieces and 
transplanted subcutaneously into the right hind-leg of anaesthetized mice (120 
mg/kg body weight (b.w.) ketamine intraperitoneal (i.p.) and 16 mg/kg b.w. xylazine 
i.p.). Volume doubling time (VDT) were calculated as previously described, data on 
FaDU, UT-SCC-5, UT-SCC-14, UT-SCC-15 and XF354 were previously reported15. 
Tumour irradiation and analysis of local control data  
Irradiation experiments have been previously reported in detail12,15,16. Briefly, local 
irradiations were given with 200 kV X-rays (0.5 mm Cu filter, 1 Gy/min) when the 
tumour reached a diameter of 7mm (range: 7–9mm). Fractionated irradiations were 
given under ambient conditions with 30 doses within 6 weeks. For single dose 
irradiation under homogeneous hypoxia a heavy clamp was placed over the 
proximal thigh of anaesthetized mice 2 min before and during irradiation. For each 
xenograft model TCD50 was calculated for both schemes
12,15,16. 
Immunohistochemistry 
Histological evaluation of hypoxia15-17 and tumour cell proliferation (Zips et al, in 
press 18) have been previously reported in detail. Briefly, tumour bearing animals 
were injected with the hypoxia cell marker pimonidazole (Natural Pharmacia 
International Inc., Research triangle park, NC) and the S-phase marker BrdU (Serva, 
Heidelberg, Germany), both 0.1 mg/g b.w. i.p. dissolved in 10 mg/ml NaCl 0.9%, 1 
hour and 15 minutes before tumour excision, respectively. For hypoxia staining, 
sections were incubated with rabbit anti-pimonidazole polyclonal antibody (kindly 
provided by Dr. J. Raleigh, Institute of Radiation Oncology, University of North 
Carolina Medical School, Chapel Hill, NC) followed by a secondary goat anti-rabbit 
FITC polyclonal antibody (Jackson ImmunoResearch, West Grove, PA). The hypoxic 
fraction (HF) was determined as the pimonidazole positive area per viable tumour 
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area. For detection of proliferation, sections were probed with biotinylated 
monoclonal anti-BrdU antibody (DakoCytomation, Glostrup, Denmark) followed by 
addition of streptavidin-peroxidase complex and DAB chromogen. BrdU LI was 
determined by manually counting positive and negative cells per high-power visual 
field (400-fold) in 10 fields. Five tumours (2 central cross-sections per tumour) were 
evaluated per tumour model. One tumour for CAL33 did not show positive cells and 
was left out. The staining procedure failed in HSC-4 and UT-SCC-45 tumours. 
 
Table 3.1  Summary of previously determined tumour parameters 
 Immunohistochemistry TCD50 ([Gy]) (95% CI) 
Tumour type 
Hypoxic fraction (HF [%]) 
mean ± sd Fractionated radiation Single dose clamp 
CAL33 29.3 ± 12.8 105.2  (90-141) 66.1 (54-105) 
FaDu 11.7 ± 5.4 85.2     (77-96) 48.3   (44-53) 
HSC4+ 20.2 ± 7.1 82.9   (69-107) 52.4   (46-63) 
SAS 21.0 ± 10.7 126.7 (114-140) n.d. 
UT-SCC-5 35.2 ±  8.0 117.2 (103-140) 62.7   (54-74) 
UT-SCC-8 14.2 ± 5.8 52.1     (40-61) 44.9   (41-50) 
UT-SCC-14 6.2 ± 2.1 52.1     (46-59) 42.0   (37-47) 
UT-SCC-15 23.6 ± 11.6 78.1   (63-109) 54.1   (46-70) 
UT-SCC-45 18.1 ± 7.4 45.4     (38-52) 45.5   (40-55) 
XF354 19.4 ± 8.2 47.4     (40-55) 46.6   (39-62) 
sd: standard deviation 
95% CI: 95% confidence interval 
n.d.: not determined 
+ tumour evokes residual immune response in nude mice 
Data have been reported in12,15-17. The HF value for UT-SCC-15 was erroneously reported in these 
publications. 
 
RNA isolation, Microarrays and Signature evaluation 
Total RNA was extracted with Trizol reagent (Sigma, Saint Louis, MO) according to 
the manufacturer’s instructions. RNA quantity and quality was determined using the 
ND-1000 spectrometer (NanoDrop Technologies) and RNA Nano LabChip kit on the 
2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA), respectively. 
Affymetrix HG-U133 Plus 2.0 GeneChips were used for gene expression profiling of 
the ten xenograft lines. Total RNA was pooled in equal amounts from 2 or 3 
independent xenografts, dependent on the quality of the RNA. Biotin-labeled cRNA 
was synthesized from 2 μg of pooled RNA with the Affymetrix One-Cycle target 
Chapter 3 
 
50 
labeling. For hybridization 20 μg cRNA was used. The manufacturer’s standard 
protocols were strictly followed (Affymetrix, Santa Clara, CA).  
The Bioconductor19 packages affy20, affyPLM21 and simpleaffy21 were used to 
evaluate the quality of the hybridized arrays and the quality of the pre-processing. 
GCRMA was performed used for background correction and normalization of the 
gene expression microarrays. An expression filter was applied to remove probes 
with low expression across the samples. With the Bioconductor package 
genefilter21, probes with an expression value below 100 in 50% of the arrays were 
excluded. 
The genes in the signature were mapped to the microarray and expression data of 
these genes was extracted. Next, a signature score was calculated for each 
xenograft model. This score was defined as the weighted average expression value 
of the genes in the signature (Equation 1). Details on the methodology and weight 
assignment were previously described 6. 
N
exp  w
  Score
N
1i
ii
=
⋅
=       Equation (1) 
With: Score = signature score 
 N = number of genes in the signature 
 i = gene i 
 wi = weight of gene i 
 expi = gene expression of gene i  
The signature score for each signature of interest was correlated with various 
endpoints which have been determined in the ten different xenograft models12,15,17. 
Pearson’s correlation and linear regression were performed (p < 0.05 was 
considered significantly different).  
Results 
A comprehensive HNSCCs xenograft set was used to introduce a novel gene 
signature evaluation procedure. Gene expression microarray profiling was 
performed for xenografts grown from 10 HNSCC lines. Per model three individual 
tumours were grown. RNA was isolated and pooled in equal amounts for each 
tumour type. For CAL33, UT-SCC-14 and UT-SCC-45 RNA was pooled from two 
tumours, because RNA quality was not sufficient in the third tumour. 
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Table 3.2 Signature overview 
Gene signature Reference Number of genes Phenotype 
Chi hypoxia Chi et al7 171 Hypoxia 
0% early hypoxia Seigneuric et al8   79 Hypoxia 
2% early hypoxia Seigneuric et al8   36 Hypoxia 
Wound signature Chang et al5 454 Wound response 
IGS Liu et al13 176 Stemness 
Proliferation Starmans et al6 110 Proliferation 
Chung signature Chung et al22   42 - 
 
Several published gene expression signatures were evaluated in this xenograft 
dataset. Since proliferation, hypoxia and ‘stemness’ are implicated in determining 
outcome of radiotherapy, signatures related to these phenotypes were included in 
this study. We also included a prognostic signature specific for surgery and chemo-
radiation treated Head and Neck cancer patients14,22.  An overview of the studied 
signatures is given in Table 3.2. For each xenograft model a signature score was 
calculated for each signature (Equation 1). This signature score was then correlated 
to different phenotypic tumour features. 
 
Table 3.3 Summary of determined tumour parameters 
 Immunohistochemistry Tumour growth rate 
Tumour type BrdU labelling index (BrdU LI [%]) 
mean ± sd 
Volume doubling time (VDT [days]) 
median (10-90 percentiles) 
CAL33 9.56 ± 1.9 4.26   (3-6) 
FaDu 11.88 ± 5.8 4.48   (3-6) 
HSC4+ n.d. 3.80   (2-6) 
SAS 22.57 ± 6.9 4.15   (3-6) 
UT-SCC-5 11.63 ± 3.7 6.79   (5-9) 
UT-SCC-8 9.23 ± 3.0 6.23   (4-9) 
UT-SCC-14 6.48 ± 1.8 4.18   (3-7) 
UT-SCC-15 11.21 ± 2.8 6.03   (4-8) 
UT-SCC-45 n.d. 6.91 (4-10) 
XF354 10.62 ± 3.0 8.69 (5-12) 
sd = standard deviation 
n.d. = not determined 
+ tumour evokes residual immune response in nude mice 
 
Several tumour features were previously studied for this set of xenografts. HF was 
earlier determined by immunohistochemistry with pimonidazole15,17. Further 
Yaromina et al12 previously studied the TCD50 after fractionated irradiation (30 
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fractions, 6 weeks) or under clamping conditions (single dose). These parameters 
are displayed in Table 3.1. For this study two additional parameters were calculated. 
VDT and BrdU LI were assessed for each xenograft line. Data of these 
measurements are given in Table 3.3. 
We first tested whether proliferation signatures accurately reflect more direct 
measures of tumour growth such as BrdU LI and VDT. We postulated that both the 
proliferation and Wound signature would correlate with BrdU LI. For the 
proliferation signature this does not need further explanation; however for the 
Wound signature this hypothesis is not immediately obvious. We have previously 
shown that the proliferation and Wound signature identify the same patients in 
several large microarray patient datasets6, which could indicate that these 
signatures are measures for the same process, in this case proliferation. Figure 3.1A 
and 3.1B show the association between BrdU LI and the proliferation and the 
Wound signature, respectively. Both signatures show a strong correlation with BrdU 
LI (r: 0.66 and 0.72, respectively). For the Wound signature this correlation is 
significant (p = 0.044). The proliferation signature only shows a borderline 
significant result (p = 0.077). For both signatures no correlation was found with VDT 
(proliferation signature: r: 0.22, p = 0.550, Wound signature: r: -0.12, p = 0.739). For 
completeness correlation coefficients were also calculated for the other tumour 
parameters, no additional correlations were found (Table 3.4). 
 
Table 3.4 Results of correlating gene signatures to xenograft features 
 Immunohistochemistry In vivo properties 
 HF BrdU LI VDT TCD50 TCD50clamp 
Gene signature r p r p r p r p r p 
Chi hypoxia 0.01 0.973 -0.47 0.245 -0.35 0.324 0.08 0.825 0.22 0.579 
0% early hypoxia 0.04 0.903 0.87 0.005 -0.19 0.604 0.45 0.194 0.01 0.988 
2% early hypoxia -0.18 0.625 0.62 0.103 0.23 0.522 0.05 0.896 -0.34 0.378 
Wound signature -0.18 0.628 0.72 0.044 -0.12 0.739 0.21 0.558 -0.26 0.504 
IGS -0.64 0.048 0.35 0.394 -0.36 0.304 -0.05 0.884 -0.51 0.161 
Proliferation -0.02 0.959 0.66 0.077 0.22 0.550 0.08 0.825 -0.19 0.620 
Chung signature 0.33 0.360 0.30 0.477 0.04 0.921 0.23 0.521 0.25 0.510 
r    : Pearson’s coefficient of correlation 
p   : p-value for linear regression 
 
Further we hypothesized that the different hypoxia signatures would correlate with 
HF. Pearson’s coefficients of correlation indicated that there was no association 
between the three hypoxia signatures and HF (Table 3.4, Figure 3.2A-C). 
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Correlations between the signatures and all other tumour features were calculated 
to investigate whether the hypoxia signatures were associated with other tumour 
parameters. The 0% early hypoxia signature showed a strong significant correlation 
with BrdU LI (Figure 3.1C, r: 0.87, p = 0.005). Also the 2% early hypoxia signature 
related to BrdU LI (Figure 3.1D, r: 0.62, p = 0.103). The Chi hypoxia signature, unlike 
the other two hypoxia signatures showed a negative association with BrdU LI 
(Figure 3.1E, r: -0.47, p = 0.245). 
 
 
Figure 3.1 
Correlation between BrdU LI and the proliferation signature (A), the Wound signature (B), the 
0% early hypoxia signature (C), the 2% early hypoxia signature (D), the Chi hypoxia signature 
(E) and the IGS signature (F) respectively. Dotted lines indicate linear fit for (border) 
significant correlations. 
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Further for the 0% hypoxia signature a trend with TCD50 (fractionated irradiation) 
was observed, although this was not significant (r: 0.45, p = 0.194). The other 
hypoxia signatures showed no correlation at all with TCD50 (Table 3.4). 
For the invasiveness gene signature (IGS), a ‘stemness’ related signature, and Chung 
signature no hypotheses were phrased. We only speculated that the IGS signature 
would not correlate with BrdU LI. Our group previously demonstrated in a set of 
large patient microarray datasets that the IGS and proliferation signature identify 
different patients6. This could indicate that these signatures track different 
processes. To explore what features might be associated with the IGS and Chung 
signature, correlations were calculated between the signatures and all tumour 
phenotype parameters (Table 3.4). No substantial relation between the IGS 
signature and BrdU LI was found (Figure 3.1F, r: 0.35, p = 0.394). Results showed a 
significant negative correlation between the IGS signature and HF (Figure 3.2D, r: -
0.64, p = 0.048) and a negative association with TCD50 under clamping conditions (r: 
-0.51, p = 0.161). No correlations were found for the Chung signature (Table 3.4). 
 
 
Figure 3.2 
Correlation between HF and the 0% early hypoxia signature (A), the 2% early hypoxia 
signature (B), the Chi hypoxia signature (C) and the IGS signature (D) respectively. Dotted 
lines indicate linear fit for (border) significant correlations. 
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Discussion 
Better understanding of tumour behaviour is necessary to improve and individualize 
cancer treatment. To date, the most important factors used to predict outcome and 
choose therapy modalities are tumour size, site, stage and grade. However, these 
factors cannot explain biologic behaviour nor treatment response. 
Published gene signatures were evaluated in a comprehensive human tumour 
xenograft dataset, consisting of 10 different HNSCC cell lines. We included gene 
signatures related to proliferation, hypoxia and ‘stemness’, since these phenotypes 
are important for outcome of radiotherapy9-14. We show that both the proliferation 
signature and the Wound signature correlate with BrdU LI. It was previously 
suggested that many signatures track a common set of biologic phenotypes23. 
Further Whitfield et al24 postulated that for many signatures this would be 
proliferation. We previously provided data that supports this idea6. Surprisingly two 
hypoxia signatures showed no association with HF, however they also showed a 
strong positive correlation with BrdU LI. Previously gene ontology analyses already 
showed that genes involved in proliferation and cell cycle were enriched in these 
signatures8. This suggests that these two hypoxic signatures might be rather 
surrogate markers for proliferation than hypoxia signatures. However the IGS 
signature, a ‘stemness’ related signature, showed a strong negative correlation with 
HF. This appears contradictory to recent suggestions that hypoxia may confer stem-
like properties or provide a niche for stem cells25,26. This result will need to be 
further investigated. 
Here gene expression profiling, immunohistochemistry and assessment of in vivo 
tumour properties were performed in different xenografts within one experiment. 
We tried to account for this by pooling RNA from three individual tumours for 
microarray profiling. Ideally, all measurements should be obtained from the same 
set of tumours. Due to this and the small number of microarrays used, probably 
only strong correlations can be identified. Signatures associated with multiple 
phenotypes then only demonstrate weak associations. This might explain why no 
correlations were found for the Chung signature. 
We introduce a new signature evaluation step that could be applied to overcome 
part in the shortcomings of gene signature research. Any signature of interest can 
be evaluated with this in vivo procedure. A signature can be compared to different 
immunohistochemical parameters and in vivo xenograft properties. This will help 
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with the biological interpretation of signatures derived from clinical studies. For in 
vitro derived signatures it introduces an extra validation step, ensuring that the 
signature also tracks the process of interest in a complex tumour 
microenvironment. 
Conclusion  
We show that gene expression profiling in parallel with immunohistochemistry and 
assessment of tumour properties in a set of xenograft models can advance clinical 
interpretation of gene signatures. 
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Abstract 
Background: Previously we demonstrated that an mRNA signature reflecting cellular 
proliferation had strong prognostic value. Since clinical applicability of signatures 
can be controversial, we sought to improve the clinical utility of our marker by 
validating its biological relevance, reproducibility in independent datasets, and 
applicability using an independent technique, quantitative polymerase-chain-
reaction (qPCR). 
Methods and Findings: To facilitate signature evaluation with qPCR a novel 
computational procedure was used to reduce the number of signature genes 
without significant information loss. These genes were biologically validated in 
different human cancer cell lines upon serum starvation and in a panel of 168 
xenografts. Expression of the qPCR-based signature was dramatically decreased 
under starvation conditions and inversely correlated with tumor volume doubling 
time in xenografts. 
Analyses were then extended to large patient cohorts: 1820 breast cancers and 858 
non-small-cell lung cancers (NSCLC). The signature validated in breast cancer 
(Hazard ratio [HR] 1.63; P < 0.001) and NSCLC adenocarcinoma (HR 1.64; P < 0.001) 
microarray datasets. 
Lastly, qPCR in a node-negative, non-adjuvantly treated breast cancer cohort (n = 
129) showed that patients assigned to the high proliferation group had worse 
disease-free survival than those in the low proliferation group (HR 2.25; P < 0.05). 
This prognosticity was most pronounced in stage I tumors (HR 5.92; P < 0.001). 
Conclusions: We have developed and validated a qPCR-based proliferation 
signature. This test might be used in the clinic to select (early-stage) patients for 
specific treatments that target proliferation. 
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Introduction 
Over the last decade, gene expression microarray technology has had a profound 
impact on cancer research. The ability to analyze the expression of thousands of 
genes in a single experiment has been systematically used to derive prognostic and 
predictive markers for many cancer types1-4. Numerous of these “signatures” show 
good prognostic power, but surprisingly gene-wise overlap between them has been 
minimal5-8 which increases the difficulty of introducing microarrays in clinical 
practice. Moreover, studies comparing data originating from different microarray 
platforms have reported poor inter-platform correlations9,10. Nevertheless, multiple 
studies in breast and non-small-cell lung cancer (NSCLC) have shown that most of 
these signatures exhibit similar prognostic performance and identify identical 
patients7,11. These data suggest that, although gene-wise overlap is small, the 
signatures track common underlying biology that determine patient outcome. 
Among others, Weigelt et al.12 have suggested that proliferation genes drive the 
prognostic power of these signatures11,13,14. A large meta-analysis by Wirapati et 
al.15 supports this concept. 
To determine if this result could be clinically useful, we previously developed a 
signature based on 104 proliferation genes16. This signature was derived from two 
in vitro gene expression datasets. Genes were selected that showed a cycling 
pattern after synchronization in one dataset and responded to serum stimulation in 
the other. Our proliferation signature exhibited strong prognostic power in several 
large transcriptome datasets representing different cancer types16. Further, the 
proliferation signature and multiple other signatures identified similar patients as 
having good or poor prognosis16. These results substantiate the hypothesis that 
many published signatures act as surrogates of proliferation. 
The clinical applicability of gene expression signatures remains controversial; 
studies seem to lack consistency and external validation is not straightforward8,17-21. 
Many gene expression signatures were developed since the introduction of gene 
expression microarray technology, however so far only in breast cancer two 
prognostic gene profiles are tested in large prospective trials12,15,22,23. The 
dimensionality of gene expression microarrays makes statistical analysis complex, 
and large numbers of samples are required for reproducible results8,24. An approach 
to only evaluate a select number of transcripts may therefore provide an efficient 
alternative to high throughput expression profiling. The use of a PCR-based test to 
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evaluate the proliferation signature would assist in the application to a clinical 
setting25. Furthermore, a PCR-based technique does not necessitate the availability 
of fresh-frozen tissue, whereas this is recommended for gene expression 
microarrays26. Many more samples might thus be available to validate classifiers 
with a PCR-based technique. 
Initially we examined whether it was possible to reduce the number of genes in the 
proliferation signature, without deteriorating its prognostic value. The original 
signature consisted of 104 genes, and so reducing this number would make data 
collection, analysis and transfer to a PCR-based approach simpler and more 
transparent. To further facilitate translation of this reduced proliferation signature 
to a PCR-platform a series of in vitro and ex vivo validation experiments were 
performed. We reduced the proliferation signature to 10 genes and validated it in 
1820 breast cancer and 862 NSCLC patients. Lastly the reduced proliferation 
signature was applied to another independent, 129-patient breast cancer cohort 
with qPCR to demonstrate clinical utility.  
Materials and methods 
Gene size reduction 
In our original study16 we developed a 104-gene proliferation signature and 
evaluated it in five different microarray datasets representing breast, lung, and 
renal cancers27-31. To reduce the size of the signature, each gene was tested for its 
univariate prognostic value in each dataset. This was for disease-specific27,30, 
metastasis-free28 or overall29,31 survival, depending on what was reported for the 
dataset. Only genes that had fewer than 25% missing values were included. 
Expression of each gene was used as a continuous variable as input for receiver 
operator curve (ROC) analysis. Genes were ranked within each dataset by the area 
under the receiver operator curve (AUC) (Supplementary Data File S1), and then 
subjected to a rank-based filtering. The filtering criteria were dependent on the 
number of datasets that included a certain gene, and were: 
- Present in 1/5 dataset:   Discard the gene 
- Present in 2/5 datasets: Select when ranked in top 20 for both datasets 
- Present in 3/5 datasets: Select when ranked in  top 20 in all three datasets 
- Present in 4/5 datasets: Select when ranked in top 20 in 3 out of 4 datasets 
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- Present in 5/5 datasets: Select when ranked in the top 20 in 4 out of 5 
datasets 
qPCR 
RNA was reverse-transcribed using I-script (Bio-Rad) and quantitative PCR was 
performed in ABI 7500 (Applied Biosystems). Gene abundance was detected using 
power SYBR Green I (Applied Biosystems). Primer sequences are provided in 
Supplementary Data File S2. Relative abundance of every gene per sample 
(Xgene,sample) was calculated using standard curves and normalization to 18S rRNA 
signal (equation 1). This was followed by median scaling per gene for each dataset32. 
18S
T
gene
T
sample gene, slope
C
 - 
slope
C
  X sample 18S,sample gene,=     Equation (1) 
A multi-gene signature score was subsequently calculated for the reduced 
proliferation signature as follows: 

=
=
N
1n
n expr,gene  Score       Equation (2) 
In which N is the number of genes in the multi-gene marker. The parameter 
geneexpr,n for a sample equals the value 1 if the sample has a level of gene n above 
the median for all samples in the dataset and -1 otherwise. All data analyses were 
performed in R (v2.12.1). 
In vitro validation 
To validate the involvement in proliferation of the genes in the reduced signature, 
serum starvation experiments were performed in five cancer cell lines (MCF7, HeLa, 
HT-29, U-2 OS and DU145). Cells were grown either in normal serum containing 
medium (10% fetal bovine serum, FBS), the control situation, or in low serum 
containing medium (0.1% FBS, starvation condition) for 48 hours. RNA was isolated 
for both conditions for three biological replicates. The multi-gene signature score 
(Equation 2) was calculated for each sample. Scores were then compared between 
normal and serum starvation conditions with a two sample two-tailed unpaired 
Student’s t-test (R v2.12.1). 
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Ex vivo validation with PCR 
A large set of xenografts (n = 168) was used to assess whether it is feasible to 
evaluate the reduced proliferation signature in tumor material. Material was 
isolated from xenografts grown from different cancer cell lines (HeLa, HT-29, U-87, 
LS 174T, HCT 116 and Hep G2) obtained from previous studies in which tumor 
volume doubling times (VDTs) were calculated33-36. The multi-gene signature score 
(Equation 2) was calculated and used to median dichotomize the xenograft samples. 
Differences in tumor VDTs were then assessed between the two groups with a two 
sample two-tailed unpaired Student’s t-test (R v2.12.1). 
Validation in independent microarray datasets 
The reduced proliferation signature was further validated in independent public 
mRNA abundance datasets. Several breast cancer37-47 and NSCLC1,37,48-50 datasets 
were used to assess the prognostic power of the reduced proliferation signature. 
For NSCLC the datasets reported on adenocarcinoma and/or squamous cell 
carcinoma. Considering these are completely different disease types, separate 
analyses were performed per subgroup. When overall survival was provided this 
was used as endpoint, otherwise disease-specific survival (or the closest variant 
available) was used. All datasets used Affymetrix microarrays, which were 
normalized using the RMA algorithm51 (R packages: affy v1.26.1) combined with 
updated ProbeSet annotations52 (R packages v12.1.0: hgu95av2hsentrezgcdf, 
hgu133ahsentrezgcdf, hgu133bhsentrezgcdf and hgu133plus2hsentrezgcdf). Genes 
were matched across datasets based on Entrez Gene IDs. Median scaling and 
housekeeping gene normalization (to the geometric mean of ACTB, BAT1, B2M and 
TBP levels) was performed32. The multi-gene signature score (equation 2) was used 
to median dichotomize the patients in a dataset. Patients predicted as having good 
or poor prognosis in any of the datasets were pooled into different groups. This was 
done for the breast cancer and lung cancer datasets separately. Prognostic 
performance of the reduced proliferation signature was evaluated by Cox 
proportional hazard ratio modeling followed by the Wald test (R survival package 
v2.36-2). For breast cancer 15-year survival was used as end-point and 5-year 
survival for NSCLC.  
Validated PCR-based proliferation signature 
 
65 
Validation in independent patient cohort 
The reduced proliferation signature was evaluated using qPCR in a breast cancer 
patient cohort of the breast tumor bank of the Radboud University Nijmegen 
Medical Centre (Nijmegen, The Netherlands) as described previously53. Patients 
underwent modified radical mastectomy or a breast-conserving lumpectomy 
between November 1987 and December 1997. Postoperative radiotherapy was 
administered, to the breast after an incomplete resection or after breast-conserving 
treatment, or to the parasternal lymph nodes when the tumor was medially 
localized. Patients did not receive (neo-) adjuvant systemic therapy according to the 
standard treatment protocol at the time. RNA was available from 129 lymph-node 
negative breast cancer patients. 
qPCR was carried out to evaluate the reduced proliferation signature in this patient 
cohort. Subsequently the multi-gene signature score (Equation 2) was calculated 
and patients were either assigned to the low or high expression group. Patients in 
the low expression group are predicted to have good prognosis whereas patients in 
the high expression group are predicted to have poor prognosis. Disease-free 
survival was used as follow-up end point. Univariate and multivariate Cox 
proportional hazard ratio modeling followed by the Wald test was used to evaluate 
the reduced proliferation signature (R survival package version 2.36-2). For a 
subgroup of the cohort histological grade was unknown, median imputation was 
applied for those patients (R e1071 package v1.5-24). Moreover multivariate 
models with and without the signature were evaluated with the C-index (R survival 
package v2.36-2). 
 
Table 4.1 The reduced proliferation signature 
Gene Symbol Entrez Gene ID Name 
BUB1B 701 Budding uninhibited by benzimidazoles 1 homolog beta (yeast) 
CCNA2 890 Cyclin A2 
CCNB2 9133 Cyclin B2 
FANCI 55215 Fanconi anemia, complementation group I 
MELK 9833 Maternal embryonic leucine zipper kinase 
NCAPH 23397 Non-SMC condensing I complex, subunit H 
RRM2 6241 Ribonucleotide reductase M2 
SKA3 221150 Spindle and kinetochore associated complex 3 
UBE2C 11065 Ubiquitin-conjugating enzyme E2C 
UBE2T 29089 Ubiquitin-conjugating enzyme E2T (putative) 
Chapter 4 
 
66 
Results 
To reduce the number of genes in the proliferation signature, genes were ranked 
according to their individual prognostic power in each of the 5 datasets used in the 
original study (Supplementary Data File S1)16. After filtering and gene ranking, the 
final reduced proliferation signature consisted of ten genes, which is a reduction of 
90% (Table 4.1). 
The original basis of the proliferation signature was in gene expression studies 
carried out in vitro. To ensure that the remaining genes accurately reflect 
proliferation status per se, especially when assessed by qPCR, we evaluated the 
reduced signature both in vitro and ex vivo. First, five different cancer cell lines 
(MCF7, HeLa, HT-29, U-2 OS and DU145) were cultured in either normal or serum-
starved conditions. Figure 4.1A shows that expression of the reduced proliferation 
signature was significantly lower upon serum starvation compared to control 
growing conditions (P = 1.52 x 10-11, t-test). Individual genes showed a similar 
pattern (Supplementary Figure S4.1). 
 
 
Figure 4.1 
In vitro and ex vivo qPCR validation of the reduced proliferation signature. Difference in 
reduced proliferation signature score in normal versus starvation conditions were compared 
in a series of cell lines (A). A set of xenografts (n = 180) was dichotomized in a low and a high 
proliferation group based on the reduced proliferation signature and corresponding volume 
doubling times (VDTs) were compared (B). 
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We then assessed expression of the 10 genes in a panel of tumor xenografts with 
known volume doubling times (VDTs)33-36 originating from different cancer cell lines. 
Xenografts were assigned to either the low or high proliferation group based on 
expression of the reduced proliferation signature. Although proliferation rate is not 
expected to be the only parameter which influences gross tumor growth (e.g. rates 
of cell turnover are also important) we hypothesized that VDTs in the group with 
high proliferation should be reduced compared with xenografts with low 
proliferation. Figure 4.1B confirms this hypothesis: a significant difference in VDTs 
between high- and low-proliferation signature xenografts was observed (P = 5.32 x 
10-6, fold-change 

 ionproliferat  highionproliferat  low VDT/VDT   = 1.60; t-test). 
To demonstrate its prognostic power, the reduced signature was evaluated in two 
large gene expression-based meta-datasets of 1820 breast and 862 NSCLC patients. 
None of these datasets were included in the original study; all were fully 
independent. 
Patients were stratified based on the reduced proliferation signature and Cox 
proportional hazards modeling was used to assess performance. Patient 
classification with the reduced proliferation signature could stratify breast (Figure 
4.2A: HR = 1.63; 95% CI 1.39 - 1.92; P = 1.42 x 10-9 Wald test) and NSCLC patients 
(Figure 4.2B: HR = 1.35; 95% CI 1.10 - 1.66; P =34.47 x 10-3 Wald test) into groups 
with distinct prognostic profiles. High expression of the reduced proliferation 
signature correlated with poor survival in all patient groups. For NSCLC subgroup 
analyses were performed for the adenocarcinoma and squamous cell carcinoma 
patient groups, for these are significantly distinct disease states. NSCLC 
adenocarcinoma patients could be grouped into cohorts with significantly different 
survival properties (Figure 4.2C: HR = 1.64; 95% CI 1.30 – 2.06; P = 3.01 x 10-5 Wald 
test). However in the squamous cell carcinoma cohort the reduced proliferation 
signature had no prognostic power (Figure 4.2D: HR = 0.66; 95% CI 0.41 - 1.04; P = 
7.14 x 10-2 Wald test). In Supplementary Figures S4.2 and S4.3 Kaplan-Meier survival 
curves for the individual datasets are provided. These data indicate that reduction 
of the proliferation signature was successful; the reduced signature could stratify 
patients into groups with significant differences in survival. 
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Figure 4.2 
Validation of the reduced proliferation signature in a breast (A) and non-small cell lung (B) 
cancer meta-dataset. For NSCLC a subgroup analysis was performed (adenocarcinoma (C) and 
squamous cell carcinoma (D)). [HR: hazard ratio, P: p-value Wald test]. 
 
To confirm the prognostic performance of the reduced proliferation signature when 
evaluated by qPCR, we tested its performance in a further independent cohort of 
129 lymph-node negative breast cancer patients. This patient group is distinct from 
those used for model development and from those in the meta-dataset analysis. 
Table 4.2 displays patient and treatment characteristics. The reduced proliferation 
signature stratified the cohort into groups predicted to have either good (low 
proliferation) or poor prognosis (high proliferation). Figure 4.3A shows that the 
patient group predicted to have poor prognosis had significantly worse disease-
specific survival than the good prognosis group (HR = 2.25; 95% CI 1.01 - 4.99; P = 
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4.60 x 10-2 Wald test). The majority of this cohort were stage I patients, therefore a 
subgroup analysis was performed. The reduced proliferation signature could stratify 
stage I patients in two groups with highly significant differences in prognosis (Figure 
4.3B: HR = 5.92; 95% CI 1.62 - 21.59; P= 7.03 x 10-3 Wald test). 
To investigate whether the signature’s prognostic power was independent of other 
clinical factors multivariate Cox proportional hazard ratio modeling was used. In the 
whole patient cohort the reduced signature performed comparable to stage 
(Supplementary Table S4.1), however it did, like the other factors included, not 
reach statistical significance (HR = 1.73; 95% CI 0.73 - 4.12; P= 0.215 Wald test). In 
stage I patients the reduced proliferation signature was the top prognostic factor 
(Table 4.3, HR = 7.23; 95% CI 1.65 - 31.95; P= 8.57 x 10-3 Wald test). C-indexes for 
multivariate Cox proportional hazard ratio models of clinical parameters with and 
without the reduced proliferation signature were calculated. Both in the whole 
cohort and stage I patient group adding the signature increased prognostic power, 
in the stage I patient group the signature alone outperformed the model comprising 
clinical parameters (Supplementary Table S4.2). 
 
 
Figure 4.3 
Validation of the reduced proliferation signature with qPCR in a breast cancer patient cohort; 
for the whole patient group (A) and only stage I patients (B), respectively. [HR: hazard ratio, 
P: p-value Wald test]. 
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Table 4.2 Baseline demographics of breast cancer patients in low and high risk groups assessed with the 
reduced proliferation signature (full characteristics were presented previously53) 
Factor All patients 
(N = 129) 
Low risk 
(N = 61) 
High risk 
(N = 68) 
P* 
Surgery    0.371 
Mastectomy 55 23 32  
Lumpectomy 74 38 36  
Radiotherapy    0.935 
Yes 84 39 45  
No 45 22 23  
Stage of disease    0.004 
I 78 46 32  
II 48 14 34  
III 3 1 2  
Grade+    0.142** 
G1 9 5 4  
G2 48 25 23  
G3 40 13 27  
Not recorded 32 18 14  
Histological type    0.017 
Ductal 90 45 45  
Lobular 19 12 7  
Other 20 4 16  
Menopauzal    0.928 
Pre 26 13 13  
Post 103 48 55  
Treatment    0.121 
Lumpectomy + radiotherapy 74 38 36  
Mastectomy 44 21 23  
Mastectomy + radiotherapy 11 2 9  
*   p value χ2-test 
** without including those with missing or unknown values 
+  grading was performed according to Bloom and Richardson, by the method modified by Elston and 
Ellis54 
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Table 4.3 Results multi-variate Cox regression model stage I patient group (78 patients) 
Factor HR CI p 
Reduced proliferation signature 7.23 1.65 - 31.6 0.009 
Grade (vs. grade 1)    
Grade 2 0.79 0.14 - 4.36 0.783 
Grade 3 0.17 0.02 - 1.36 0.095 
Histological type (vs. ductal)    
Histological type lobular 0 0.00 -   inf  0.998 
Histological type other 2.02 0.54 - 7.64 0.298 
Age 0.99 0.90 - 1.11 0.992 
Menopauzal (pre vs. post) 0.95 0.06 - 14.7 0.970 
Treatment (vs. lumpectomy + radiotherapy)    
Mastectomy 2.99 0.79 - 11.3 0.106 
Discussion 
We previously reported a microarray-based proliferation signature with high 
prognostic power in several large microarray datasets encompassing different 
cancer types. Here, we successfully reduced the number of genes in the 
proliferation signature to a more appropriate scale for low throughput technologies. 
This could greatly facilitate the translation into a clinically applicable test25. In two 
large independent gene expression meta-datasets for breast and NSCLC the 
reduced signature separated the patients into groups with significant distinct 
survival properties. 
A subgroup analysis for the NSCLC cohort showed high prognostic power in 
adenocarcinoma patients, whereas in squamous cell carcinoma patients no 
prognostic power was observed. Earlier studies have shown similar data for other 
measures of proliferation; high proliferation was significantly associated with 
incidence of metastasis and worse survival in adenocarcinomas, but not in 
squamous cell carcinomas55,56. Recapitulating decreasing the number of signature 
genes resulted in a new marker with high performance across different cancer 
types. 
Several genes in the signature have previously been implicated in cancer 
outcome14,57-60. UBE2C (ubiquitin-conjugating enzyme E2C) expression was 
correlated with malignant progression in thyroid carcinomas and demonstrated 
prognostic power in ovarian cancer61-63, in which high expression was associated 
with worse survival. Over-expression of RRM2 (ribonucleotide reductase M2) 
showed association with chemotherapy resistance64. Furthermore, a large fraction 
Chapter 4 
 
72 
of the published gene expression signatures include clusters of proliferation-
associated genes and several of the reduced proliferation genes are represented in 
these clusters1,12,65,66. 
As a last step the reduced proliferation signature was evaluated with qPCR in an 
independent breast cancer patient cohort. This patient group consisted entirely of 
patients without axillary lymph node metastases, and who did not receive systemic 
adjuvant therapy, making it possible to distinguish a pure prognostic value of the 
proliferation signature. The reduced proliferation signature stratified patients into 
groups with different survival properties and showed high prognostic power 
especially in stage I patients. A high disease-specific survival was observed in the 
stage I patients identified as having low risk. This suggests the reduced proliferation 
signature might be useful in identifying high risk stage I breast cancer patients that 
could benefit from additional therapy like chemo-radiation or accelerated 
radiotherapy, whereas the low risk group would not.   
Currently two large prospective trials have been started to address the predictive 
performance of two gene expression signatures in early breast cancer22,23. Both 
these signatures include a subset of proliferation genes and several meta-analyses 
show evidence that the prognostic value of these signatures is mostly attributed to 
this process12,15. Therefore a signature reflecting merely proliferation could make its 
interpretation easier. Furthermore the prognostic power of the reduced 
proliferation signature was not limited to breast cancer; it also had a high 
performance in a NSCLC adenocarcinoma meta-dataset. 
Thus, we here show that the array based proliferation signature could be reduced 
to 10 genes. This reduced proliferation signature can be applied in small tissue 
samples, including possibly FFPE material, adding to its clinical applicability. The 
pure prognostic power of the signature was validated in an independent breast 
cancer patient cohort, where it was shown to be particularly useful to select 
patients that would benefit from more aggressive therapy. To fully grasp the 
potential prognostic or predictive role of the signature it further should be tested in 
prospective trials and translated from a relative to an absolute measure. 
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Supplementary figures and tables 
 
Figure S4.1 
In vitro validation of the individual genes in the reduced proliferation signature. Difference in 
normalized, scaled expression between normal and starvation conditions in a panel of cell 
lines are shown. 
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Figure S4.2 
Validation of the reduced proliferation signature in the individual breast cancer datasets used 
for meta-dataset analysis (HR: hazard ratio, p: p-value Wald test). 
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Figure S4.3 
Validation of the reduced proliferation signature in the individual non-small cell lung cancer 
datasets used for meta-dataset analysis (HR: hazard ratio, p: p-value Wald test). 
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Table S4.1 Results multi-variate Cox regression model (129 patients) 
Factor HR CI p 
Reduced proliferation signature 1.73 0.73 - 4.12 0.215 
Stage (vs. stage I)    
Stage II/III 1.75 0.76 - 4.00 0.185 
Grade (vs. grade 1)    
Grade 2 0.71 0.15 - 3.34 0.667 
Grade 3 0.70 0.14 - 3.48 0.663 
Histological type (vs. ductal)    
Histological type lobular 0.94 0.26 - 3.37 0.930 
Histological type other 1.90 0.79 - 4.58 0.154 
Age 0.99 0.95 - 1.04 0.663 
Menopauzal (pre vs. post) 0.52 0.13 - 2.12 0.359 
Treatment (vs. lumpectomy + radiotherapy)    
Mastectomy 1.49 0.63 - 3.55 0.367 
Mastectomy + radiotherapy 0.66 0.13 - 3.29 0.616 
 
Table S4.2 Results C-index calculation 
Model All patients Stage I patients 
Signature 0.603 0.735 
Clinical parameters 0.674 0.692 
Clinical parameters + signature 0.686 0.826 
Clinical parameters (without histological grade) 0.668 0.656 
Clinical parameters (without histological grade) + signature 0.682 0.787 
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Abstract 
Background: Highly parallel analysis of gene expression has recently been used to 
identify gene sets or ‘signatures’ to improve patient diagnosis and risk stratification. 
Once a signature is generated, traditional statistical testing is used to evaluate its 
prognostic performance.  However, due to the dimensionality of microarrays, this 
can lead to false interpretation of these signatures. 
Principle findings: A method was developed to test batches of a user-specified 
number of randomly chosen signatures in patient microarray datasets. The 
percentage of random generated signatures yielding prognostic value was assessed 
using ROC analysis by calculating the area under the curve (AUC) in six public 
available cancer patient microarray datasets. 
We found that a signature consisting of randomly selected genes has an average 
10% chance of reaching significance when assessed in a single dataset, but can 
range from 1% to ~40% depending on the dataset in question. Increasing the 
number of validation datasets markedly reduces this number. 
Conclusions: We have shown that the use of an arbitrary cut-off value for evaluation 
of signature significance is not suitable for this type of research, but should be 
defined for each dataset separately. Our method can be used to establish and 
evaluate signature performance of any derived gene signature in a dataset by 
comparing its performance to thousands of randomly generated signatures. It will 
be of most interest for cases where few data are available and testing in multiple 
datasets is limited. 
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Introduction 
In recent years, DNA microarray technology has been increasingly used in oncology. 
It has provided insight into the biological mechanisms underlying tumour formation 
and identified new therapy targets1,2. However, most studies performed in this field 
identify gene sets, or so-called signatures, which can be used to improve diagnosis 
and risk stratification3-6. These signatures can be acquired through supervised 
analysis methods7. Both patient microarray and clinical data are directly used to find 
the genes that correlate with tumour type or patient outcome8-12. Also biology-
based signatures can be used for patient prognosis, which are usually derived from 
in vitro microarray data2,13-15. Though the performance of these classifiers can be 
very high in the dataset studied, application of these signatures in other datasets is 
often limited and data reproduction is not straightforward16. Furthermore, 
signatures identified in comparable studies show little overlap in gene content1,10,17-
20. Michiels et al.4 showed that identified gene lists were highly variable within one 
dataset and depended on the patients included in the training set. Further, they 
demonstrated that several published gene classifiers did not classify patients better 
than by chance. They stress that validation is an important issue in microarray 
research. Fan et al.21 repeated and extended these analyses 5 years later and made 
similar conclusions. Moreover Boutros et al.19 amongst other showed that the use 
of different statistical procedures could identify multiple highly prognostic 
signatures from one dataset22,23. An extensive analysis of the effect of different 
statistics on ranked gene lists showed large variability24. 
A major challenge with DNA microarray technology is to take account of variability 
across a very large number of parameters1. This variability arises from several 
sources: the biological samples, hybridisation protocols, scanning, and image and 
statistical analysis7. In a recent review, Dupuy et al.1 demonstrated that proper 
methodology in pre-processing and statistical analysis is essential in these sorts of 
studies. They found that a large subset of published microarray studies show flaws 
in the applied analysis; serious mistakes are made in the selection of genes and 
inadequate control of multiple testing is performed. The issue of multiple testing is 
crucial, as microarrays monitor the expression of thousands of genes, while the 
number of samples is relatively small. 
Statistical significance of the differences in gene expression patterns for different 
patient groups or tumour types is often determined with traditional statistical 
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testing procedures, such as the two-sample t-tests or Wilcoxon rank sum tests1,7,20. 
These procedures are challenged with serious multiplicity and without employment 
of a correction for multiple testing, the number of false positives will be extremely 
high. Various methods have been developed to overcome this problem of 
identifying differentially expressed genes and are used to create gene 
signatures11,19,20,25. 
More importantly multiple testing is often not considered in evaluating the 
prognostic power of signatures. Once a signature is created, its prognostic power is 
determined with traditional survival statistics and standard cut-off values for 
significance. We hypothesise that this can lead to high numbers of false prognostic 
signatures when the number of evaluated datasets is limited. Therefore we sought 
to develop a simple method to take into account the high-dimensionality of 
microarrays in the phase of evaluating signature prognosticity.   
To quantify the problem of multiple testing we have developed a method to test 
batches of random signatures in microarray datasets. We show that the average 
chance that a random signature produces a prognostic result in one dataset is 
approximately 10% but can range from 1% to ~40%. Increasing the number of 
datasets reduces this false positive rate significantly. As a result of this high degree 
of variability amongst datasets, we developed a method that can be used to 
determine an appropriate threshold level of significance that must be reached for a 
given signature. This is done by testing a set of randomly chosen signatures along 
with the signature of interest within the dataset under investigation. 
Materials and methods 
Random signature testing 
A method to test the prognostic value of random gene signatures of a predefined 
size on a microarray dataset was developed in Matlab (Matlab 7.1, The Mathworks, 
Natick, MA, USA). Unless indicated otherwise, analyses were performed using this 
program. The program creates a user-specified number of random gene sets, 
consisting of a user-specified number of genes. For a given dataset all genes on the 
respective microarray were used to create the random signatures. This batch of 
random signatures was then tested on a dataset by means of a signature score 
calculation. 
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Datasets 
Patient microarray and clinical follow-up data were collated to test the random 
gene sets. Datasets are publicly available in the microarray databases Gene 
Expression Omnibus (GEO: http://www.ncbi.nlm.nih.gov/projects/geo/) and 
Stanford Microarray Database (SMD: http://genome-www.stanford.edu 
/microarray) and elsewhere. Accessory clinical and follow-up data were also given 
or provided by the authors on request. Table 5.1 provides an overview of the 
datasets and the databases, where these are accessible. Data filtering and pre-
processing is explained in the supplementary data. 
Signature score calculation 
Expression data of the genes in a signature was extracted from the dataset. The 
following step was used to calculate a signature score for each patient included in 
the dataset. This score was defined as the average expression value of the genes in 
the signature (Equation 1). When a gene was represented by more than one 
reporter on an array, the expression of the reporters was averaged before signature 
calculation. The signature scores for each patient were then coupled to the survival 
data of the patients. The signature score was used to median dichotomize the 
patient cohorts. 
N
exp
  Score
N
1i
mi,
=
=       Equation (1) 
Where: Score, signature score; N, number of genes in the signature; expi,m, gene 
expression of gene i in sample m. 
In a second setup expression of the genes in the signature were used for K-nearest 
neighbor classification (KNN) combined with leave-one-out-cross validation 
(LOOCV). With this method one patient is withheld and the class membership of this 
patient is predicted using the KNN model (knnclassify function in Matlab) built on 
the remaining patients. The event parameter of the survival data was used as 
training class. This procedure was repeated for each patient, resulting in a class 
prediction for the whole cohort. 
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Table 5.1 Overview of the analysed patient microarray datasets. 
Dataset Cancer 
type 
# patients 
with survival 
data 
# UnigeneIDs 
on array 
Average # reporters 
measured per 
UnigeneID 
Source 
Miller Breast 
cancer 
236 20,647 1.97 GEO accession GSE3494: 
http://www.ncbi.nlm.nih.
gov/projects/geo/ 
Wang Breast 
cancer 
286 12,867 1.61 GEO accession GSE2034: 
http://www.ncbi.nlm.nih.
gov/projects/geo/ 
van de Vijver Breast 
cancer 
295 18,781 1.21 http://microarray-
pubs.stanford.edu/wound
_NKI/ 
Zhao Renal 
cancer 
177 5,640 1.40 SMD: 
http://smd.stanford.edu/ 
Beer Lung 
cancer 
86 5,396 1.15 http://dot.ped.med.umic
h.edu:2000/ourimage/pu
b/Lung/index.html 
Garber Lung 
cancer 
24 4,936 1.15 SMD: 
http://smd.stanford.edu/ 
Analysis 
The signature scores, median dichotomized groups or KNN classifications were 
evaluated with the area under the curve (AUC) of the receiver operator curve (ROC). 
Definitions for AUC calculations are as follows: 
- True positive: patient in the high score group that died from disease 
- False positive: patient in the high score group that is alive 
- True negative: patient in the low score group that is alive 
- False negative: patient in the low score group that died from disease 
 A signature score was considered prognostic when the AUC is ≤0.4 or ≥0.6. This cut-
off value was based on the AUCs of several published gene signatures evaluated in 
the study of Ntzani et al.26 (further details are given in the results section and 
supplementary data). 
Results 
In order to assess the potential for identifying prognostic gene signatures by chance 
alone in microarray based datasets a method was developed to test the prognostic 
value of batches of randomly generated signatures. Six different publicly available 
microarray datasets with follow-up data were used (Table 5.1). These six datasets 
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differ in number of patients, number of measured genes, number of reporters 
measured per gene, as well as platform and type of cancer. 
For each dataset separately 5 batches of 10,000 random signatures were generated 
and tested. In each batch the number of genes (UnigeneIDs) in a gene set was 
predefined. The number of genes (UnigeneIDs) in the five batches were 10, 25, 50, 
100 and 200 respectively. For example, the first batch included 10,000 random 
signatures, each consisting of ten genes. For each signature a patient score was 
derived, defined as the average of the expression of the genes in a signature 
(Equation 1). Each signature score was then tested for prognostic value by ROC 
analysis and determination of the AUC. Figure 5.1A-F shows the distribution of the 
AUCs for the first batch of 10,000 random signatures for the different datasets. 
To define a reasonable cut-off value for the AUC values, we first searched for AUCs 
used in published gene signatures. However, the majority of studies do not evaluate 
gene signatures using the AUC. Most gene signatures are evaluated with Kaplan-
Meier survival curves and log-rank tests. Kaplan-Meier survival analyses and ROC 
analyses are linked; a high AUC corresponds to a good separation in distinct survival 
groups. To be able to define a cut-off, we calculated the AUCs for the different gene 
sets as evaluated in the review by Ntzani et al.26. The calculated AUCs as well as 
additional information are provided in the supplementary data. Based on these 
calculations we chose the cut-off values AUC ≤0.4 and ≥0.6. 
In Figure 5.1G the percentage of signatures that passed the criteria for the different 
batches of signatures are given. These percentages range from 1% to ~40%, 
dependent on the dataset and the number of genes in the signatures. Table 5.2 
provides the average, standard deviation as well as maximum and minimum AUC 
for the analyses with the gene sets consisting of ten genes. These data show that 
the larger the standard deviation, the higher the chance that a randomly generated 
signature is considered prognostic. Further, the maximum and minimum AUC show 
that very high signature performances can be found at random. 
 
Table 5.2 A batch of 10,000 random signatures of 10 genes was tested in the six datasets. 
Dataset Average (± standard deviation) AUC Maximum AUC Minimum AUC 
Miller 0.505 ± 0.054 0.692 0.312 
Wang 0.475 ± 0.043 0.644 0.329 
van de Vijver 0.499 ± 0.073 0.744 0.297 
Zhao 0.472 ± 0.048 0.666 0.333 
Beer 0.502 ± 0.073 0.753 0.249 
Garber 0.536 ± 0.118 0.938 0.031 
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Figure 5.1 
 Random signature AUC distribution in different published microarray datasets (A: Miller, B: 
Wang. C: van de Vijver, D: Zhao, E: Beer and F: Garber dataset) for batches of 10,000 random 
gene sets with 10 genes evaluated with receiver-operator curves. The percentages of random 
gene sets passing the AUC criteria AUC ≤ 0.4 or AUC ≥ 0.6 for different signature sizes are 
displayed in G. 
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Table 5.3 A batch of 1,000,000 random signatures of 10 genes was tested in the six datasets. 
Dataset Average (± standard deviation) AUC Maximum AUC Minimum AUC 
Miller 0.503 ± 0.044 0.688 0.290 
Wang 0.475 ± 0.042 0.691 0.303 
van de Vijver 0.511 ± 0.072 0.778 0.209 
Zhao 0.472 ± 0.048 0.699 0.283 
Beer 0.503 ± 0.073 0.831 0.196 
Garber 0.539 ± 0.117 1.000 0.000 
 
Sampling 10,000 gene sets is a small number compared to the total number of 
possible gene sets. In order to show that the 10,000 random gene sets are sufficient 
to estimate the AUC distribution, we tested batches of 1,000,000 signatures 
consisting of 10 genes in the six datasets. The AUC distributions for this permutation 
study were similar to the distributions for the batches of 10,000 gene sets (Table 
5.3). 
From the differences between the six datasets (Table 5.1), it could be that the 
number of patients, the number of genes (UnigeneIDs) and the number of reporters 
measured per gene influence the probability that a randomly chosen signature is 
considered prognostic. To further investigate the impact of these parameters, the 
Miller dataset was used. To determine the influence of patient number, the dataset 
was split in halves and in quarters. For these partial datasets the same five batches 
of 10,000 random signatures were tested. The influence of the number of genes 
was tested by splitting the dataset in half, this time based on genes rather than 
patients. Again, five batches of 10,000 random signatures were tested. To 
investigate the influence of the number of reporters measured per gene, again a set 
of five batches of 10,000 genes was tested on the dataset, considering only genes 
with more than one reporter. This was repeated, but for each gene only one 
reporter measurement was considered. Of these parameters only patient number 
influenced the false discovery rate. Results of the analysis to determine the 
influence of the number of genes and the number of reporters measured per gene 
are given in the supplementary data. 
Influence of patient numbers 
It has already been reported in previous studies26,27 that the number of patients 
influences the false discovery rate. The Miller dataset was split into two and four 
groups respectively to confirm the importance of this factor. The same 5 batches of 
10,000 random signatures that were tested on the whole dataset were tested on 
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these subgroups (Figure 5.2A). Indeed the number of prognostic signatures 
increases dramatically when the size of the patient group decreases. To characterize 
the relationship between patient number and the probability that a randomly 
chosen signature is considered prognostic, additional analyses were performed for 
the batch of 10,000 runs with ten genes. The dataset was split into three, five and 
ten groups respectively. Figure 5.2B shows the distribution of the AUCs for the 
batch of 10,000 random signatures consisting of ten genes for the different dataset 
sizes. It is clear that the smaller the dataset, the wider and flatter the distribution 
becomes. Figure 5.2C presents the number of prognostic signatures as a function of 
dataset size. 
 
 
Figure 5.2 
The effect of dataset size was evaluated by testing batches of random gene sets on different 
subsets of the Miller dataset. 
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Effect of filtering 
One of the parameters that could account for differences in the number of 
prognostic signatures for a given dataset is filtering. To briefly explore the influence 
of filtering, two simple filtering methods were applied on the Miller dataset. After 
this filtering, again five batches of 10,000 signatures were tested. 
The first filtering procedure was to only consider reporters that had no absent calls 
in the patients. This very stringent filtering resulted in a reduction in number of 
reporters from ~45,000 to ~7,300 (approximately 5,000 unique UnigeneIDs). The 
second filtering method, often used in microarray based studies, consists of simply 
applying a threshold to the fold change. To show the effect of this step on the 
number of false positives a twofold threshold was applied.  Only genes that show at 
least a two-fold change across the patients are considered. This reduced the 
number of reporters from ~45,000 to ~23,000. 
 The results for these analyses show that both filtering methods have a different 
effect (Figure S5.1C). Fold change filtering did not influence the probability that a 
randomly chosen signature is considered prognostic; rather, it provides similar 
results to those of non-filtered analysis. Filtering for absent reporters, on the other 
hand, introduced a signature size dependency for the false positive rate. A small 
signature size resulted in a false positive rate of ~10%, whereas large signatures had 
a false discovery rate of only ~0.5%. The average, however, stands at 5-6%, similar 
to the non-filtering and fold change filtering analyses. 
Signature testing procedure 
To demonstrate that this random signature method can be used with all sorts of 
signature evaluation methods, two additional evaluation procedures were tested in 
the Miller dataset. In the previous analyses the signature score was used as 
continuous variable.  
Here we selected 10,000 random samples of 10, 25, 50, 100 and 200 genes. In the 
first setup the signature score was used to median dichotomize the patients. In the 
second setup these gene subsets were in a K-nearest neighbor classification (KNN) 
combined with leave-one-out-cross validation (LOOCV). Both procedures results in 
patient classification into two groups, which were then coupled to outcome and 
evaluated by the AUC. Similar AUC distributions are obtained with these different 
signature evaluation procedures, exact distributions characteristics differ slightly 
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(Table 5.4). The numbers of random gene sets passing the criteria are comparable 
(Supplementary Figure S5.1D). 
 
 
Figure 5.3 
Proposed workflow for random signature testing procedure. 
 
Table 5.4 Batches of 1,000,000 random signatures of 10, 25, 50, 100 and 200 genes were tested in the 
Miller dataset, where three different signature evaluation procedures were used. 
% UnigeneIDs in 
signature 
Signature score 
 
Average AUC 
(± standard deviation) 
[min - max] 
Median dichotomized 
 
Average AUC 
(± standard deviation) 
[min - max] 
KNN with LOOCV 
 
Average AUC 
(± standard deviation) 
[min - max] 
10 0.505 ± 0.054 0.535 ± 0.045 0.553 ± 0.036 
 0.312 – 0.692 0.348 – 0.702 0.426 – 0.717 
25 0.507 ± 0.054 0.535 ± 0.045 0.558 ± 0.033 
 0.313 – 0.692 0.338 – 0.690 0.412 – 0.697 
50 0.509 ± 0.055 0.538 ± 0.045 0.561 ± 0.031 
 0.304 – 0.694 0.374 – 0.671 0.457 – 0.678 
100 0.513 ± 0.053 0.540 ± 0.044 0.562 ± 0.030 
 0.319 – 0.682 0.352 – 0.679 0.435 – 0.689 
200 0.518 ± 0.052 0.543 ± 0.043 0.562 ± 0.029 
 0.335 – 0.684 0.373 – 0.688 0.449 – 0.691 
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Table 5.5 Evaluating 4 published signatures with the random signature testing procedure in three breast 
cancer datasets. 
 Wound signature 
Dataset p-value 
log rank test 
HR 
[95% CI] 
p-value 
Wald test 
AUC p-value 
Z-test 
Miller 0.001 2.48 [1.40 – 4.41] 0.002 0.671 0.002 
Wang 0.016 1.59 [1.08 – 2.36] 0.017 0.597 0.001 
van de Vijver 7.27 10-9 4.15 [2.42 – 7.04] 7.71 10-8 0.688 0.018 
 IGS signature 
Dataset p-value 
log rank test 
HR 
[95% CI] 
p-value 
Wald test 
AUC p-value 
Z-test 
Miller 5.28 10-4 2.66 [1.49 – 4.78] 7.93 10-4 0.645 0.010 
Wang 8.11 10-5 2.17 [1.45 – 3.25] 1.17 10-4 0.644 5.80 10-5 
van de Vijver 2.16 10-6 3.12 [1.88 – 5.15] 6.35 10-6 0.668 0.038 
 Early 0% 
Dataset p-value 
log rank test 
HR 
[95% CI] 
p-value 
Wald test 
AUC p-value 
Z-test 
Miller 0.014 2.00 [1.13 – 3.53] 0.015 0.601 0.083 
Wang 0.051 0.69 [0.47 – 1.02] 0.055 0.452 0.001 
van de Vijver 0.786 1.06 [0.67 – 1.67] 0.785 0.508 0.162 
 Early 2% 
Dataset p-value 
log rank test 
HR 
[95% CI] 
p-value 
Wald test 
AUC p-value 
Z-test 
Miller 0.026 1.85 [1.06 – 3.22] 0.027 0.593 0.105 
Wang 0.545 0.89 [0.61 – 1.32] 0.558 0.498 0.045 
van de Vijver 0.321 1.25 [0.80 – 1.97] 0.321 0.549 0.418 
 
Evaluating signatures by random testing 
To show that the random signature testing method is a valuable tool in microarray 
based studies, several published gene signatures were tested. In short, the 
suggested procedure to test a signature in a dataset is as follows (Figure 5.3). For 
the signature of interest the AUC was calculated in the dataset, additionally the AUC 
distribution for batches of random signatures with a similar size as the signature of 
interest was computed. The signature AUC was then compared to the random 
signature AUC distribution with a Z-test to assess whether the signature of interest 
performed better than could be expected by chance. 
The Wound signature13, “invasiveness gene signature” (IGS)10 and two early hypoxia 
signatures15 are recently published gene signatures. For the Wound and IGS 
signatures it was previously shown that these signatures had high prognostic value 
in different datasets and cancer types10,13,28. The two early hypoxia signatures 
however, were only evaluated in one dataset15. These signatures were evaluated in 
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the three breast cancer datasets8,29,30 with the signature score (details are provided 
in the supplementary data). 
For the Miller dataset also Kaplan-Meier survival analyses were performed, since 
the two early hypoxia signatures were previously tested in this dataset. The results 
of Kaplan-Meier survival analyses and the random signature testing are given in 
Table 5.5 and Figure S5.3. From the Kaplan-Meier survival analyses all four 
signatures seemed to have a high prognostic value (p-values log-rank test <0.05). 
However the random signature testing procedure indicated that the two early 
hypoxia signatures did not perform better than chance in that dataset. Testing the 
four signatures in the other two breast cancer datasets indeed showed that the two 
early hypoxia signatures did not have prognostic value (p-values log-rank test 
>0.05). For the Wound and IGS signatures both evaluation procedures indicated 
that the performance of these signatures is high in the different datasets and that 
this is unlikely due to chance. 
Discussion 
We assessed six patient microarray datasets spanning different cancer types, 
numbers of patients and arrays to evaluate the effect of false positives on gene 
signature evaluation. Different-sized batches of 10,000 random signatures were 
tested in all datasets. With the given threshold, the average chance that a randomly 
generated signature was considered prognostic was approximately 10%, but ranged 
from 1% to ~40%. 
Testing batches of random signatures in different datasets revealed that the AUC 
distribution varied widely between datasets. Choosing an arbitrary cut-off value for 
significance is then clearly not suited for gene signature evaluation. Rather a 
dataset-based cut-off value should be considered. The random testing method we 
propose here can be applied to calculate the level of AUC necessary to reach 
significance beyond random for a given signature size in a given dataset. 
The random testing procedure can also be used to directly test whether the 
performance of a certain signature could be due to chance. A schematic overview is 
given in Figure 5.3. A batch of random signatures with the same size as the 
signature of interest can be tested along with the original signature. The AUC 
distribution of the random signatures can then be used to statistically test whether 
the original signature performs better than random. An equivalent permutation-
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based validation step was used by Boutros et al.19 to evaluate their signature; this 
step provided significant information on the prognostic performance of the gene 
set. 
We have shown that proper validation is absolutely essential in gene signature 
research. This supports several previous studies, which have argued that signature 
performance is often overestimated due to improper validation in a large number of 
studies1,26. For several analyses, the maximum and minimum AUC were also 
calculated. We show that random signatures can have very high performances 
(AUC>0.9), which further supports this observation. 
A method to overcome this multiple testing problem is validation in multiple 
independent datasets. We have shown that testing random signatures in two 
datasets decreased the chance that a random signature is called prognostic 
dramatically (Figure S5.2). However it is not always possible to validate a gene 
signature in multiple datasets. In oncology most microarray studies focus on breast 
and lung cancer, for these sites there are a lot of public datasets available that can 
be used for validation. Therefore this technique is not primarily meant for these 
cancer types, but rather for tumour types where only few data, in terms of the 
number of samples and number of datasets, are available; for those cases this 
technique would be valuable. By comparing the performance of four published 
signatures in one patient microarray dataset with Kaplan-Meier curves all signatures 
seemed to have prognostic value. However, applying the random testing procedure 
in that dataset already indicated that two out of four signatures did not perform 
better than chance. Testing the four signatures in multiple datasets indeed showed 
that these two signatures did not show prognostic value in the other datasets. 
From the analyses on all six datasets, several parameters could influence the 
number of false positives. To assess the effect of these variables, several 
parameters were manipulated in one of the datasets. However, of the tested 
parameters, only patient number influenced the false positive rate dramatically. The 
need for large patient groups to obtain reliable results has already been recognised 
in other studies. Ntzani et al.26 evaluated 84 microarray studies and concluded that 
small studies often give inflated, over-promising results. Zien et al.27 assessed the 
influence of the number of samples in a different way: a simulation model was 
applied in which specificity and sensitivity were measured depending on changes in 
sample size, technical and biological variability. They showed that with small sample 
sizes, sensitivity and specificity were highly dependent on the biological and 
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technical variance, whereas larger sample sizes led to quite robust results that were 
less dependent on biological and technical variance. Moreover Popovici et al.23 
tested the effect of training set size on the performance of the trained marker in a 
validation dataset. Overall signature performance improved in the validation data 
and better concordance between training and testing results was observed when 
training dataset size increased.  
Testing batches of random generated gene sets in different gene expression 
microarray datasets showed that the use of an arbitrary cut-off value for evaluation 
of signature significance is not suitable. Further it is important to use the same 
signature evaluation procedure for the random gene sets as for the signature of 
interest, since the AUC distribution can differ when using a different method. 
Thresholds should be defined for single datasets separately in order to obtain 
reproducible results. This permutation method can be used to establish and 
evaluate signature performance of any derived gene set within single or multiple 
datasets by comparing its performance to the performance distribution of 
thousands of randomly generated signatures. However it will be of most interest for 
cases where limited data is available. 
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Supplementary material and methods 
Data filtering and pre-processing 
Datasets downloaded from the SMD31,32 were filtered according to the parameters 
in the paper. CloneIDs were chosen as gene annotation and the data obtained was 
log-transformed. For the normalized affymetrix arrays29,30 the genes were log-
transformed. The Beer et al.33 dataset was already pre-processed therefore to 
perform log-transformation all expression values below 1.1 were set to 1.1, this was 
similar to the processing performed by Chen et al.34. In all other cases the data were 
kept in downloaded, log-transformed format8. CloneIDs and affymetrix probeIDs 
were translated into UnigeneIDs (Build199) with Source (http://smd.stanford.edu/) 
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or Affymetrix data files (Affx annotation files available at www.affymetrix.com). 
Datasets were imported in Matlab. 
AUC cut-off value definition 
Ntzani et al.26 evaluated the performance of different gene sets by means of 
sensitivity and specificity. These parameters were used to calculate the AUC. In their 
study they evaluated the performance of gene sets during cross-validation (Figure 1 
upper panel in Ntzani et al.26), on independent validation (Figure 1 lower panel in 
Ntzani et al.26) and based on unsupervised approaches (Figure 2 in Ntzani et al.26). 
For each of the three figures we calculated the AUC for each data point. In 
Supplementary Table S5.1 the sensitivity, specificity, AUC and dataset size are 
provided for the three figures. From these data it is obvious that during cross-
validation the performance of gene sets is high, as expected. Further it is clear that 
the performance of gene sets is better when datasets are small. 
In Supplementary Table S5.2 the average AUC is calculated for the three figures. The 
use of small datasets often leads to overestimated results26,27; thus, we also 
calculated the average AUC by omitting datasets smaller than 10, 20, 30, 40 and 50 
patients respectively. 
To define a threshold for AUC, not all data are included. During cross-validation the 
performance of a gene set is optimized and high values for AUC are found; 
therefore, these are omitted. Further, in our study five out of six datasets included 
>> 50 patients. Based on these calculations a threshold of ≤0.4 or ≥0.6 was chosen. 
Evaluation of published signatures 
The four published signatures evaluated here10,13,15 consist of gene that are both 
upregulated and downregulated in a certain phenotype. Therefore the definition of 
the score was slightly different form the score used for the random batches of 
signatures; a weighted average was used (Equation 2). For the Wound signature 
weights of -1 and 1 were assigned to genes representing a quiescent and activated 
wound response respectively.  For the IGS signature log ratios were provided in the 
supplementary data of the paper, a weight of 1 is assigned to genes with a positive 
log ratio and a weight of -1 to genes with a negative log ratio. The two early hypoxia 
signatures contained only genes that are upregulated early in hypoxia, therefore all 
weights were 1. 
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   Equation (2) 
Where: Score, signature score; N, number of genes in the signature; wi, weight of 
gene I and expi,m, gene expression of gene i in sample m. 
Patients were subsequently grouped into a high and a low risk group for each 
signature by median dichotomization of the signature scores. Kaplan-Meier survival 
curves with log-rank tests and Cox proportional hazard ratio modelling were 
performed to address survival differences between the two groups. 
Supplementary results 
Influence of number of genes 
The number of genes (UnigeneIDs) might influence the probability that a randomly 
chosen signatures is considered prognostic. To test this, the Miller dataset was used 
again. This time the dataset was split in two based on the genes, and five batches of 
10,000 random signatures were tested on each part. Supplementary Figure 5.1A 
shows that the percentage of prognostic signatures is not influenced by the number 
of genes present on the microarray. To ascertain that the influence of the number 
of genes is negligible the dataset was split in ten, based on the genes. A run of 
10,000 random signatures consisting of ten genes was performed. This showed that 
splitting the dataset into more groups based on the number of genes did not result 
in a change in the false positive rate. The average chance of finding a prognostic 
result at random was 6.9% ± 0.8 for the ten groups, similar to the number found for 
the whole dataset. 
Influence of the number of reporters measured per gene 
Also the number of reporters measured per gene could influence the probability 
that a randomly chosen signature is considered prognostic. To test this hypothesis 
only the genes represented by more than one reporter on the Miller dataset were 
taken into account. The Miller dataset has approximately 10,000 UnigeneIDs 
(genes) that are represented by multiple gene identifiers (probes in the microarray). 
First, five batches of 10,000 random signatures, consisting only of the genes 
mentioned, were tested. In the second run of five batches, only one reporter per 
gene was taken into account from this list. If the number of reporters per gene plays 
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a role, considering only one rather than multiple reporters was thought to increase 
the change that a randomly chosen signature was considered prognostic. The 
results given in Supplementary Figure 5.1B show that the number of reporters per 
gene did not influence the false positive rate. 
Validation in multiple datasets 
To show that the probability that a randomly chosen signature is considered 
prognostic will substantially decrease when random signatures are tested in two 
independent datasets, five batches of 10,000 random signature runs were once 
more performed, however now the batches of signatures were tested on two 
datasets in parallel. It is clear that the van de Vijver and Beer dataset had the 
highest number of false positives overall, therefore these datasets were analyzed in 
parallel. The results of the 10,000 runs on the two datasets, both separately and 
combined (presented in Supplementary Figure 5.2), show that the chance of finding 
a prognostic result at random dropped from ≥15% to ≤5% by combining the two 
datasets. Addition of another independent dataset will further decrease this 
number. 
Supplementary figures and tables 
 
Figure S5.1 
 The effect of number of genes (A), number of probes per gene (B), filtering (C) and signature 
evaluation procedure (D) was tested in the Miller dataset. 
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Figure S5.2 
Evaluation if random gene sets in two datasets (van de Vijver and Beer dataset). 
 
 
Figure S5.3 
Kaplan-Meier survival analysis of 4 published gene signatures (A: Wound signature, B: IGS 
signature, C: early hypoxia 0% signature and D: early hypoxia 2% signature). 
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Table S5.1 Calculated AUC for the gene sets evaluated in the review by Ntzani et al.26 
Figure 1 upper panel Ntzani et al.26 
Dataset Sensitivity Specificity AUC Dataset size 
1 45 95 0.70 60 
2 90 70 0.80 78 
3 100 100 1 10 
4 65 65 0.65 86 
5 100 90 0.95 29 
6 70 70 0.70 31 
7 55 85 0.70 58 
8 100 100 1 33 
9 85 85 0.85 20 
Figure 1 lower panel Ntzani et al.26 
Dataset Sensitivity Specificity AUC Dataset size 
1 100 70 0.85 19 
2 90 50 0.70 180 
3 60 65 0.625 43 
4 45 65 0.55 64 
5 40 55 0.475 58 
6 70 65 0.675 80 
7 85 90 0.875 27 
8 75 100 0.875 6 
Figure 2 Ntzani et al.26 
Dataset Sensitivity Specificity AUC Dataset size 
1 80 50 0.65 60 
2 25 100 0.625 49 
3 40 90 0.65 78 
4 40 80 0.60 55 
5 75 65 0.70 47 
6 40 85 0.625 86 
7 55 100 0.775 24 
8 10 100 0.55 125 
9 70 80 0.75 16 
10 80 75 0.775 29 
11 55 85 0.70 15 
12 90 65 0.775 39 
13 55 80 0.675 40 
14 40 80 0.60 240 
15 70 65 0.675 40 
16 100 40 0.70 21 
17 80 100 0.90 20 
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Table S52 Average AUC for the gene sets evaluated in the review by Ntzani et al.26 depending on dataset 
size threshold. 
Figure 1 upper panel Ntzani et al.26 
Threshold dataset size # of datasets included Average AUC 
None 9 0.817 
10 8 0.794 
20 7 0.786 
30 6 0.758 
40 4 0.713 
50 4 0.713 
Figure 1 lower panel Ntzani et al.26 
Threshold dataset size # of datasets included Average AUC 
None 8 0.703 
10 7 0.679 
20 6 0.65 
30 5 0.605 
40 5 0.605 
50 4 0.60 
Figure 2 Ntzani et al.26 
Threshold dataset size # of datasets included Average AUC 
None 17 0.690 
10 17 0.690 
20 14 0.670 
30 11 0.648 
40 8 0.625 
50 6 0.613 
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Subramanian and Simon reviewed mRNA-based prognostic signatures for non–small 
cell lung cancer (NSCLC)1. They concluded that many studies were poorly executed 
and that no gene expression signature is ready for clinical application. We agree 
that guidelines for design, reporting, and analysis are needed, but have reservations 
concerning the accuracy of their review. 
We examined the 20 scores that they assigned to the two signatures reported by 
our group2,3 and found several errors. The study by Lau et al.3 received a score of 0 
for “statistically significant improvement over standard risk factors” despite the fact 
that 95% confidence intervals for the difference in concordance index between a 
clinical model and a model containing clinical and molecular information were 
presented in Table A5. This table demonstrates that zero is excluded from the 95% 
confidence interval of the difference in a validation set from Duke (95% confidence 
interval 0.018 to 0.162), and was included at the far left in validation sets from 
Harvard (–0.018 to 0.079) and Michigan (–0.046 to 0.122). The study by Boutros et 
al.2 received a score of 0 for “validation in stages IA and IB”; however, Boutros et 
al.2 presented a stage-adjusted validation of 345 stage I patients in Figure S3. That 
study also provided a complete model specification readily replicable by experts in 
the field: “[Euclidean] distance between the expression profile for each patient and 
the cluster centers (medians).” Nevertheless, a score of 0 was assigned. 
With regard to the validations that Subramanian and Simon performed, we found 
that our specified procedure was not followed. They tested our three-gene 
signature3 in an independent dataset4 using data preprocessed with the Model-
Based Expression Indices with pseudo-count addition. Our method requires each 
Director’s Challenge subset to be separately pre-processed using the Robust 
Multiarray Average algorithm, with no pseudo-count addition. This change alters 
patient classification and reaffirms the need to follow author-specified procedures 
exactly. 
We also question the appropriateness of the binary scoring criteria used by 
Subramanian and Simon.  For example, a study that provides three of the four 
specified clinical covariates receives the same score as one that provides none. Of 
greater concern, a study that provides summary information receives the same 
score as one that provides individual patient annotation. Similarly, although we 
agree with Subramanian and Simon about the importance of adequate tissue 
handling, penalizing a study for not including a specific sentence detailing tissue 
handling presumes that such methods were not followed, when indeed they are 
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standard. As such, the Director’s Challenge study4, in which a strict tissue handling 
protocol was enforced and described, would be given a score of 0 for omitting this 
specific sentence. We also disagree with the authors that studies should be 
penalized for showing training set performance (i.e., resubstitution statistics). 
Although resubstitution statistics provide an optimistically biased estimate of 
performance, they still have value at a number of levels. First, it is important that all 
results are disclosed; second, the direction of effect is important; third, the 
difference between the training and validation sets is a measure of over-fitting and 
is important for future studies; fourth, demonstration of the training set 
performance allows evaluation of the signature on its initial patient population. The 
authors view resubstitution statistics as unnecessary and undesirable. We view 
them as necessary, but not sufficient, for signature evaluation. 
Finally, we believe that all datasets and validations should be published. Publication 
of failed validations provides datasets that are critical for the development and 
validation of more mature markers, and reduces negative publication bias5. Given 
the small sample sizes of existing datasets, validation in many independent patient 
populations is extremely important. According to the criteria proposed by 
Subramanian and Simon, only two datasets have appropriate patient 
characteristics, and for one of these6, the full data are not publicly available. 
There remains a strong clinical need for improved prediction of NSCLC prognosis7. A 
systematic review is timely, but the authors of such reviews — especially when 
scoring studies according to inclusion of specific data — have a responsibility to 
present complete and accurate results. 
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Abstract 
Independent validation is a critical step in the development and clinical application 
of a new biomarker. We tested two of our previously published prognostic multi-
gene markers for non-small cell lung cancer (NSCLC) in an independent 442-patient 
dataset. Both markers validated successfully in the entire cohort (3-gene marker: HR 
= 1.63, P = 0.001, 6-gene marker: HR = 1.42, P = 0.030). Further, despite being 
underpowered for a stage-specific analysis, the 3-gene marker significantly 
prognosed both Stage IB and Stage II patients. A recent report failed to replicate 
these results in the same independent dataset, so we systematically investigated 
reasons for this discrepancy. Differences in microarray pre-processing 
methodologies were identified as a key factor. By examining 24 separate pre-
processing techniques we show that minor alterations in pre-processing can change 
a successful prognostic marker (HR = 1.85; P < 0.001) into one indistinguishable 
from random chance (HR = 1.15; P = 0.348). We replicated this sensitivity to data 
pre-processing in a second dataset. Continued validation of prognostic multi-gene 
markers in independent and larger datasets is essential; proper validation must 
follow the pre-processing steps of the original study. 
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Despite improvements in staging, surgical methodologies, chemotherapy regimens 
and the addition of adjuvant therapies, 30-50% of patients with resectable non-
small cell lung cancer (NSCLC) suffer relapse and die within 5 years1-3. As more 
molecular-targeted therapies are developed, there is a clear and emerging clinical 
need for additional prognostic factors to sub-classify patients better in order to 
guide personalized therapy. 
Several groups, including our own, have employed transcriptome-profiling of 
surgically excised tumor samples to develop multi-gene prognostic markers 
(sometimes called prognostic signatures or classifiers)4-7. However, there is minimal 
gene-wise overlap between these multi-gene markers8, and challenges exist in the 
datasets and analyses used to generate them9. The Director's Challenge NSCLC 
study was an attempt to provide a large, sufficiently-powered dataset to discover 
reproducible multi-gene markers10. This study integrated four independent datasets 
of adenocarcinomas named according to the institutions at which they were 
generated: UM, HLM, MSK and CAN/DF. None of the multi-gene markers tested in 
that study were validated for the primary end-point of stage I survival. 
We previously developed two multi-gene markers derived from PCR-analysis of a 
selected group of candidate prognostic markers8,11. While independent validations 
were described in the original reports, it is critical that a good biomarker works in 
additional large patient cohorts. Therefore, we used the Director’s Challenge 
dataset to interrogate the validity of our two multi-gene markers. We followed the 
exact procedures described in the original studies (see Supplementary Material) and 
evaluated our markers using stage-adjusted Cox proportional hazards models. Both 
our 3-gene marker (Figure 7.1A; HR = 1.63, P = 1.18 x 10-3, Wald test) and 6-gene 
marker (Figure 7.1B; HR = 1.42, P = 3.01 x 10-2, Wald test) successfully validated. 
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Figure 7.1 
 The previously published 3-gene8 (A) and 6-gene11 (B) markers were validated in the DC 
dataset10. Power calculations were performed (C) prior to a sub-stage analysis for the 3-gene 
marker (D: stage IA, E: stage IB, F: stage II and G: stage III). In gray a threshold line is drawn 
for power of 0.8 (C). [HR: hazard ratio, P: p-value Wald test]. 
Sensitivity to data pre-processing 
 
113 
Recently, Subramanian and Simon9 performed a critical review of a number of 
prognostic multi-gene markers for NSCLC. As part of this review, they suggested 
analyzing patients of specific stages independently and applied this approach to the 
Director’s Challenge dataset. Before embarking on a similar analysis we performed a 
power analysis to estimate the likelihood that real differences could be identified in 
each subgroup. Figure 7.1C shows that even in the large Director’s Challenge 
cohort, these sub-group analyses are marginally powered; there is only a 57% 
chance of detecting a real hazard ratio of 2.0 in stage IA patients. It is therefore not 
surprising that both our markers were ineffective at classifying stage IA patients (3-
gene marker: Figure 7.1D, HR = 0.86, P = 0.710, Wald test, 6-gene marker: HR = 
0.69, P = 0.424 Wald test). Nevertheless, the 3-gene marker was validated in stage 
IB (Figure 7.1E, HR = 2.05, P = 1.41 x 10-2, Wald test) and stage II patients (Figure 
7.1F, HR = 1.95, P = 2.11 x 10-2, Wald test). The 6-gene marker was validated in stage 
II patients (HR = 1.90, P = 3.50 x 10-2). These results emphasize the importance of 
continued validation on new datasets, as even the largest existing cohorts are 
insufficiently powered. 
As part of their review, Subramanian and Simon9 attempted to validate this same 3-
gene marker on the Director’s Challenge dataset. Surprisingly their results differed 
from those described above. They observed no validation for stage IB (P = 0.35), 
leading them to suggest that current multi-gene markers lack clinical utility. We 
investigated the origins of this discrepancy and identified differences in microarray 
data pre-processing. As described in our original report8, we used RMA-normalized 
data with each site in the Director’s Challenge treated separately. Subramanian and 
Simon9 used MBEI quantile-normalized data with pseudo-count addition, while 
treating all sites together. This issue has been appreciated in other studies where 
differences in pre-processing contributed to failed reproduction of drug sensitivity 
predictions12,13. 
To better understand the effect of different pre-processing strategies, we analyzed 
the Director's Challenge dataset using a panel of different methods and tested our 
3-gene prognostic marker against each. We investigated four separate factors. First, 
we compared treating the Director’s Challenge study as a single study or as four 
site-specific datasets (the original report indicated high inter-site variability10). 
Second, we employed four diverse and commonly-used pre-processing algorithms14-
18. Third, we evaluated the effects of log2-transformation, a standard operation in 
microarray analysis. Finally, both default Affymetrix gene annotations and updated 
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Entrez Gene-based annotations were tested19. All combinations of 2 dataset 
handling, 6 pre-processing and 2 annotation methods were evaluated, for a total of 
24 datasets. We evaluated the performance of the 3-gene prognostic marker on 
each dataset in both overall and stage-specific models (see Supplementary 
Material). Figure 7.2 outlines this procedure; Supplementary Data File 1 gives the 
classification of every patient in each dataset, and all technical details are presented 
in Supplementary Material. 
 
 
Figure 7.2 
Scheme to test marker performance sensitivity to different pre-processing schedules. The DC 
dataset10 will be pre-processed with 24 different schemes. Subsequently, the 3-gene marker8 
is evaluated. 
 
Our systematic analysis demonstrates that the validation of multi-gene markers is 
highly sensitive to data pre-processing (Supplementary Table S7.1). This is especially 
true in stage-specific analyses: hazard ratios for Stage IB patients range from 0.89 (P 
= 0.672, Wald test) to 2.05 (P = 1.41 x 10-2, Wald test). Small changes in pre-
processing led to large changes in classification performance. For example, changing 
the pre-processing algorithm from RMA to MBEI changed validation in Stage IB 
patients from success to failure (compare Figures 7.1E and 7.3A). Similarly in the 
total patient group reduced prognostic power was observed (Figure 7.1A; HR = 1.63, 
P = 1.18 x 10-3, Wald test vs. Figure 7.3B: HR = 1.36, P = 3.88 x 10-2, Wald test). 
Performance within a single method varies across stage (Figure 7.3C). 
These differences in classifier performance are caused by changes in the 
classification status of a significant portion of patients. Only 151 out of 442 patients 
are classified identically by all 24 pre-processed schemes (Figure 7.3D). About equal 
numbers of unchanged classifications are in the good (77) and poor (74) prognosis 
groups. 
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To validate that patient classification is highly affected by differences in pre-
processing the same procedure (Figure 7.2) was applied to the Bild dataset20. Again, 
only 45 out of 111 patients are classified identically across the 24 pre-processing 
methodologies (Figure 7.2E, Supplementary Data File 2) resulting in large 
differences in 3-gene marker success (Figure 7.3F, 7.3G and Supplementary Table 
S7.2). Interestingly, 3-gene marker performance improved significantly in both 
datasets when only patients identically classified with all 24 pre-processing 
schedules were considered (Figure 7.3H and 7.3I). 
 
Our findings concord with previous observations that pre-processing procedures 
influence downstream analysis of differentially regulated genes and gene 
networks14,21,22. It has been reported that the optimal pre-processing method is 
intrinsically dependent on experimental design and cannot be standardized22,23. The 
pre-processing scheme used for original validation of the 3-gene marker was again 
one of the best-performing in this second validation (Figure 7.3C). 
In summary, we report the successful validation of our 3- and 6-gene prognostic 
markers for NSCLC8 in the 442-patient Director’s Challenge dataset. Despite being 
underpowered, the marker significantly prognosed stage IB and stage II patients. In 
the course of this validation we discovered an extreme sensitivity to the pre-
processing methodology. It was recently stated that "The differences in the 
preprocessing steps for microarray data are immaterial... [when] the original 
classifier was developed using RT-qPCR."24 Our results demonstrate that this 
statement is incorrect. Instead, they indicate that different pre-processing 
methodologies can be used to identify and validate different multi-gene markers 
from the same dataset. Continued validation of prognostic multi-gene markers in 
newer and larger datasets is important, but for emerging genomic technologies it 
will be critical to exactly follow a consistent and clearly-reported data pre-
processing schedule to accurately gauge clinical applicability. 
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Figure 7.3 (previous page) 
Pre-processing influences marker validation: Changing the pre-processing algorithm (to the 
algorithm used by Subramanian and Simon9) resulted in failed validation of the 3-gene 
marker8 in the stage IB patients (A) and total cohort (B). Results for all these analyses are 
summarized in Forest plots (C). [Boxes : HR, lines: 95% confidence interval]. Classifications in 
the 24 different schedules are visualized in a heatmap (D). [White indicates a patient 
predicted to have good prognosis and black indicates a patient predicted to have poor 
prognosis. Colored sidebar displays the different pre-processing schemes, from left to right: 
algorithm (Dark grey: MBEI, White: MAS5, Light grey: RMA, Black: GCRMA), dataset handling 
(Dark grey: separate, White: merged), annotation method (White: default, Light grey: 
alternative), and log2-transformed or not (White: yes, Black: no)]. 
 
This was also tested in a second dataset20 for the 3-gene marker (E: heatmap, F: 
MAS5, separate dataset handling, default annotation; G: RMA, separate dataset 
handling, default annotation). Including only patients with identical classifications 
across all pre-processing schemes improved 3-gene marker performance in both 
datasets (H and I). [HR: hazard ratio, P: p-value Wald test]. 
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Supplementary material and methods 
Classifier evaluation 
All analyses were performed in R (version 2.11.1). The Director’s Challenge dataset10 
was used to validate our previously published 3-gene and 6-gene markers8,11. Data 
processing and patient classification were performed as in the original studies8,11. 
The data consists of four independent datasets; UM, HLM, MSK and CAN/DF. 
Shedden et al10 reported high inter-group variability in their study; therefore these 
datasets were treated separately. Further pre-processing was performed with 
RMA14 (R package: affy version 1.28.0). 
On a microarray every gene is represented by a set of oligonucleotides, called a 
ProbeSet. The annotation of these ProbeSets has changed significantly over time so 
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Dai et al.19 developed a method to generate updated ProbeSet annotations, which 
can be used as alternatives to standard annotation files provided. ProbeSet 
annotation was done with Affymetrix provided annotation (R packages: 
hgu133aprobe_2.6.0 and hgu133acdf_2.6.0), which is referred to as default. For 
marker evaluation the corresponding Affymetrix ProbeSets from the original study 
were used (Supplementary Table S7.3). Once these genes were selected, median 
scaling and housekeeping gene normalization (to the geometric mean of ACTB, 
BAT1, B2M and TBP levels) was subsequently performed, exactly as described 
previously25. 
The 3-gene classifier involves CCR7, HIF1A and STX1A. These genes were subjected 
to statistical scaling and were then median-dichotomized, as outlined in Lau et al.8 
The risk score was then calculated from the scaled, normalized expression as: 
exprexprexpr CCR7 x 3 - HIF1A x 3  STX1A x 4  Score +=  
In this equation STX1Aexpr for a patient is one if the patient has a level of STX1A 
(after applying all pre-processing schemes described above) above the median for 
all patients in the dataset and zero otherwise. The values of HIF1Aexpr and CCR7expr 
are calculated in the same way. Patients were then classified into risk groups based 
on this score. Patients with a score ≤ 2 were considered to have a good prognosis, 
whereas patients scoring more than 2 were classified as having a poor prognosis. 
For the 6-gene classifier, Euclidean distances to the training cluster centers 
(median) from the original study were calculated to classify each patient11. A patient 
was classified into the nearer cluster if the ratio of the distances between the 
profile and the two clusters was at least 0.9. 
Prognostic performance of the 3-gene and 6-gene classifier was evaluated by stage-
adjusted Cox proportional hazard ratio modeling followed by the Wald test. Five-
year survival was used as endpoint. The analysis was performed using the survival 
library in R (version 2.35-8). A power analysis was performed to estimate the 
likeliness that real differences could be identified in stage-dependent patient 
subgroups (R package: Hmisc_3.8-2). 
Dataset pre-processing 
To assess the influence of different pre-processing schedules on signature 
performance the Director’s Challenge dataset was pre-processed in 24 different 
ways. Subsequently our 3-gene classifier was evaluated in these differently pre-
processed datasets. 
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First pre-processing for the four datasets was either done for all datasets separately 
or for all combined. When datasets were treated separately pre-processing was 
performed separately for each of the four datasets. Then patients predicted as 
having good prognosis in any of the datasets were pooled into one group and 
patients predicted as having poor prognosis in any of the datasets were pooled into 
another group. Then four different pre-processing algorithms were applied; RMA14, 
GCRMA15, MAS516,17 and MBEI18 (R packages: affy version 1.26.1, gcrma version 
2.20.0). In Supplementary Table S7.4 a brief description of the algorithms is given. 
RMA and GCRMA provide data in log2-transformed space, whereas MAS5 and MBEI 
provide data in normal space. It is common to log2-transform MAS5 and MBEI pre-
processed data, and we therefore tested them both in standard and log2-
transformed space. Further ProbeSet annotation was done with default annotation 
(R packages: hgu133aprobe_2.6.0 and hgu133acdf_2.6.0), or with updated Entrez 
Gene-based annotations19, referred to as alternative (R packages: 
hgu133ahsentrezgprobe_12.1.0 and hgu133ahsentrezgcdf_12.1.0). All possible 
combinations of pre-processing (6), annotation (2) and dataset handling (2) were 
made, resulting in 24 different sets. When the default Affymetrix gene-annotation 
was applied, the corresponding Affymetrix ProbeSets from the original study were 
used. When the alternative Entrez Gene ID ProbeSet annotation was utilized, 
matching was performed based on Entrez Gene ID. Supplementary Table S7.3 below 
lists the specific ProbeSets used for each gene according to each annotation 
protocol. Supplementary Data file 1 gives the key clinical data for each patient, 
along with the good/poor classifications for the 3-gene classifier in each of the pre-
processing methods. 
A similar procedure was applied to the Bild dataset20 (R packages: affy version 
1.28.0, gcrma version 2.22.0). This dataset consists of 2 batches; therefore the same 
24 pre-processing schedules were applied. Default and alternative ProbeSet 
annotation were performed with the appropriate R packages (default: 
hgu133plus2probe_2.7.0, hgu133plus2cdf_2.7.0 and alternative: 
hgu133plus2hsentrezgprobe_13.0.0, hgu133plus2hsentrezgcdf_13.0.0). The specific 
ProbeSets used for each gene according to each annotation protocol are listed in 
Table S7.3. Supplementary Data file 2 gives the key clinical data for each patient, 
along with the good/poor classifications for the 3-gene classifier in each of the pre-
processing methods. 
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Supplementary tables 
Table S7.1 Results of (stage-adjusted) Cox proportional hazard ratio modeling 3-gene classifier for all and 
stage IB patients in the 24 different pre-processed DC datasets. Significant results (p < 0.05) are given in 
bold.  [HR: hazard ratio, P: p-value Wald test]. 
Pre-processing All patients Stage IB patients 
Algorithm Dataset Annotation Transform HR [95% CI] P HR [95% CI] P 
RMA Merged Alternative log2 
1.42 
[1.06 – 1.92] 2.07 x 10
-2 1.62 
[0.93 - 2.82] 8.87 x 10
-2 
RMA Merged Default log2 
1.64 
[1.22 – 2.21] 1.11 x 10
-3 1.80 
[1.03 - 3.14] 3.97 x 10
-2 
RMA Separate Alternative log2 
1.23 
[0.92 – 1.64] 1.72 x 10
-1 1.44 
[0.83 - 2.49] 1.90 x 10
-1 
RMA Separate Default log2 
1.63 
[1.21 – 2.19] 1.18 x 10
-3 2.05 
[1.16 - 3.62] 1.41 x 10
-2 
GCRMA Merged Alternative log2 
1.38 
[1.03 – 1.85] 2.88 x 10
-2 1.29 
[0.75 - 2.23] 3.55 x 10
-1 
GCRMA Merged Default log2 
1.40 
[1.05 – 1.88] 2.38 x 10
-2 1.54 
[0.89 - 2.66] 1.20 x 10
-1 
GCRMA Separate Alternative log2 
1.39 
[1.04 – 1.87] 2.76 x 10
-2 1.21 
[0.70 - 2.09] 5.01 x 10
-1 
GCRMA Separate Default log2 
1.43 
[1.06 – 1.91] 1.78 x 10
-2 1.54 
[0.90 - 2.66] 1.18 x 10
-1 
MAS5 Merged Alternative log2 
1.41 
[1.05 – 1.90] 2.33 x 10
-2 1.90 
[1.06 - 3.39] 3.01 x 10
-2 
MAS5 Merged Default log2 
1.46 
[1.08 – 1.97] 1.42 x 10
-2 1.84 
[1.04 - 3.26] 3.65 x 10
-2 
MAS5 Separate Alternative log2 
1.34 
[0.99 – 1.80] 5.18 x 10
-2 1.37 
[0.78 - 2.40] 2.69 x 10
-1 
MAS5 Separate Default log2 
1.55 
[1.15 – 2.08] 4.10 x 10
-3 1.82 
[1.03 - 3.19] 3.85 x 10
-2 
MAS5 Merged Alternative None 1.57 [1.17 – 2.12] 3.07 x 10
-3 1.93 
[1.10 - 3.39] 2.27 x 10
-2 
MAS5 Merged Default None 1.85 [1.37 – 2.50] 6.01 x 10
-5 1.79 
[1.02 - 3.12] 4.20 x 10
-2 
MAS5 Separate Alternative None 1.57 [1.17 – 2.11] 3.02 x 10
-3 1.59 
[0.91 - 2.77] 1.01 x 10
-1 
MAS5 Separate Default None 1.49 [1.11 – 1.99] 7.79 x 10
-3 1.68 
[0.97 - 2.92] 6.66 x 10
-2 
MBEI Merged Alternative log2 
1.15 
[0.86 – 1.54] 3.48 x 10
-1 1.19 
[0.69 - 2.06] 5.37 x 10
-1 
MBEI Merged Default log2 
1.28 
[0.96 – 1.72] 9.70 x 10
-2 1.14 
[0.66 - 1.97] 6.45 x 10
-1 
MBEI Separate Alternative log2 
1.23 
[0.92 – 1.65] 1.69 x 10
-1 1.23 
[0.71 - 2.13] 4.62 x 10
-1 
MBEI Separate Default log2 
1.36 
[1.02 – 1.83] 3.88 x 10
-2 1.32 
[0.76 - 2.29] 3.23 x 10
-1 
MBEI Merged Alternative None 1.32 [0.98 – 1.76] 6.58 x 10
-2 1.23 
[0.71 - 2.11] 4.66 x 10
-1 
MBEI Merged Default None 1.34 [1.00 – 1.80] 4.74 x 10
-2 1.10 
[0.64 - 1.90] 7.25 x 10
-1 
MBEI Separate Alternative None 1.22 [0.91 – 1.63] 1.82 x 10
-1 0.89 
[0.52 - 1.53] 6.72 x 10
-1 
MBEI Separate Default None 1.28 [0.95 – 1.72] 1.02 x 10
-1 0.94 
[0.54 - 1.62] 8.20 x 10
-1 
Sensitivity to data pre-processing 
 
121 
 
Table S7.2 Results (stage-adjusted) Cox proportional hazard ratio modeling 3-gene classifier for all 
patients in the 24 different pre-processed Bild datasets. Significant results (p < 0.05) are given in bold. 
[HR: hazard ratio, P: p-value Wald test]. 
Pre-processing All patients 
Algorithm Dataset Annotation Transform HR [95% CI] P 
RMA Merged Alternative log2 
1.54 
[0.83 – 2.86] 1.69 x 10
-1 
RMA Merged Default log2 
1.02 
[0.58 – 1.79] 9.43 x 10
-1 
RMA Separate Alternative log2 
1.08 
[0.60 – 1.94] 7.97 x 10
-1 
RMA Separate Default log2 
1.23 
[0.71 – 2.13] 4.66 x 10
-1 
GCRMA Merged Alternative log2 
1.06 
[0.58 – 1.94] 8.43 x 10
-1 
GCRMA Merged Default log2 
0.99 
[0.55 – 1.77] 9.68 x 10
-1 
GCRMA Separate Alternative log2 
0.94 
[0.51 – 1.73] 8.44 x 10
-1 
GCRMA Separate Default log2 
0.99 
[0.55 – 1.77] 9.74 x 10
-1 
MAS5 Merged Alternative log2 
0.96 
[0.52 – 1.76] 8.87 x 10
-1 
MAS5 Merged Default log2 
1.00 
[0.57 – 1.76] 9.89 x 10
-1 
MAS5 Separate Alternative log2 
1.10 
[0.64 – 1.90] 7.25 x 10
-1 
MAS5 Separate Default log2 
1.09 
[0.63 – 1.90] 7.56 x 10
-1 
MAS5 Merged Alternative None 1.64 [0.94 – 2.86] 8.48 x 10
-2 
MAS5 Merged Default None 1.65 [0.90 – 3.03] 1.03 x 10
-1 
MAS5 Separate Alternative None 1.54 [0.89 – 2.69] 1.25 x 10
-1 
MAS5 Separate Default None 1.36 [0.77 -2.40] 2.95 x 10
-1 
MBEI Merged Alternative log2 
1.10 
[0.60 – 2.00] 7.59 x 10
-1 
MBEI Merged Default log2 
1.05 
[0.57 – 1.94] 8.76 x 10
-1 
MBEI Separate Alternative log2 
1.07 
[0.60 – 1.92] 8.16 x 10
-1 
MBEI Separate Default log2 
0.85 
[0.46 – 1.57] 6.06 x 10
-1 
MBEI Merged Alternative None 1.13 [0.62 – 2.04] 6.91 x 10
-1 
MBEI Merged Default None 2.15 [1.15 – 4.03] 1.67 x 10
-2 
MBEI Separate Alternative None 1.02 [0.57 – 1.84] 9.44 x 10
-1 
MBEI Separate Default None 1.09 [0.61 – 1.95] 7.79 x 10
-1 
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Discussion 
Personalized medicine aims to deliver, to each patient, a treatment tailored towards 
their specific disease and genetics in order to achieve optimal treatment outcome 
with minimal side effects. This requires tools that can be used to select the most 
appropriate therapy regimen for specific patients. A wide variety of approaches 
from a range of research disciplines have been applied to identify prognostic and 
predictive markers to improve accuracy of treatment selection. In particular, 
approaches based on imaging1,2, serum markers3,4 and gene-expression signatures5-8 
have been identified that could be used to select patient subgroups for certain 
therapies. Advances in these research fields are creating opportunities to slowly 
move away from the one-size fits all strategy. Currently tumor staging is pre-
dominantly used to make treatment decisions for most cancer types. The work 
presented in this thesis focuses on the application of transcriptomic biomarkers for 
prognostic purposes and methods to improve their clinical utility. 
The role of proliferation in prognostic signatures 
Since the introduction of techniques for high-throughput gene-expression profiling, 
numerous gene-expression signatures have been identified that showed promising 
results in the original studies9-11. However minimal gene-wise overlap, disappointing 
validation in external datasets, and lack of consistency have lead to significant 
skepticism regarding gene expression-based classifiers12-16. On the other hand 
increasing data suggests that, although overlap in signatures is small, there is high 
consistency in their classification results. Multiple studies, including several meta-
analyses, show that prognostic gene expression markers assign a large subset of 
patients to the same prognostic groups17-21. These data support the hypothesis that 
multiple gene expression-based markers track similar underlying biology22. 
Whitfield et al23 were amongst the first to implicate a large role for proliferation in 
the prognostic capacity of these gene expression-based classifiers. Subsequent 
research provides data supportive of this concept for breast cancer20,21,24,25. 
Wirapati et al19 showed that discarding the proliferation-associated genes from a 
series of classifiers significantly deteriorated signature performance, whereas only 
focusing on this gene cluster dramatically improved prognosticity in several cases. 
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Proliferation signature 
These data stimulated us to create an in vitro-based gene expression proliferation 
marker and test classification ability across different cancer types. High 
prognosticity of this proliferation signature was observed in five patient datasets 
representing breast, non-small-cell lung and renal cancer (chapter 2). In chapter 4 
we subsequently show that conversion of our proliferation signature to a PCR-based 
test shows clinical potential in (early-stage) breast and non-small-cell lung cancer 
which can possibly be generalized across other cancer types. Markers that can be 
used across different tumor types might help elucidate what processes play a key 
role in tumorigenesis and tumor aggressiveness in general. However marker 
importance will probably not be equal for tumors of different origin site and 
different thresholds and cut-offs might apply. 
Other proliferation markers 
Proliferation substantially contributes to treatment response with both 
radiotherapy and chemotherapy26. Subsequently, overall treatment time is an 
important contributor to outcome27. Therefore, prognostic power of proliferation 
markers other than gene expression-based, like PCNA and Ki67 staining has 
extensively been studied28,29. Although mitotic rate is included in the Nottingham 
grading system for breast cancer, in general published results of these single 
indicators vary widely across multiple cancer types: some studies show high 
prognostic power whereas others show none at all28,30-34. More recently a set of 
meta-analyses on primary breast cancer reported consistently positive results for 
immunohistochemical evaluation of Ki67 as a prognostic marker35-37. Nevertheless, 
all these studies conclude that, at present, Ki67 cannot be used as a tool for risk 
group classification or therapy selection, in large part because of a lack of standard 
methodology and definition of threshold points. Studies have identified Ki67 to be 
involved in ribosomal RNA translation, however the exact functional role of Ki67 
remains unclear38,39. Ki67 is expressed at different levels throughout the cell cycle, 
with a peak expression during mitosis40. Expression is generally lost in quiescent 
cells41. In general, scoring is based on the percentage of positive stained tumor cells. 
In the aforementioned meta-data analyses reported cut-off values ranged from ~3-
40%. Until standard tissue preparation procedures, staining methods and cut-off 
points are defined, Ki67 cannot be introduced in a clinical set-up. 
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Since a measure of proliferation is included in the breast cancer grading system, and 
since evidence of the prognostic power of Ki67 is emerging, one could question the 
added value of new gene expression-based proliferation markers for breast cancer. 
Data from the two prognostic gene profiles6,9 currently approved by the FDA for 
early-stage breast cancer suggest otherwise. In multiple large patient cohorts, these 
classifiers outperform traditional clinical and histological parameters42-45. Prognostic 
capacity of both markers is significantly dependent on the contribution of 
proliferation-associated genes24. In other cancer types far less data is available on 
the performance of proliferation markers, but results from gene expression 
microarray studies including our own show the potential of gene expression-based 
classifiers for proliferation in clinical practice46,47. Evaluation of this PCR-based 
proliferation marker in large independent datasets, preferentially in a prospective 
setting, across different cancer types will elucidate the clinical applicability of this 
classifier. 
Role of other processes in transciptome-based prognosis 
Although proliferation currently seems to be the driving force in prognostic power 
of patient data-based signatures it will not be the only process with prognostic and 
possible predictive capacity at the gene expression level. A comprehensive analysis 
of Reyal et al25 encompassing several gene expression signatures and breast cancer 
datasets identified a set of modules enriched in the classification power of 
signatures which include genes involved in proliferation, immune response and RNA 
splicing. In addition various pathway-based signatures reflecting other cellular 
processes or micro-environmental features show potential. Multiple hypoxia or 
hypoxia-related gene sets have been created with prognostic power in different 
cancer types48-55. Further Carter et al7 reported a gene expression-based marker for 
chromosomal instability (CIN) that could stratify different patient datasets, 
comprising diverse cancer types, into groups with different survival properties. 
Transcriptome-based markers for different cellular processes and micro-
environmental features might thus elucidate independent prognostic power. This 
suggests that combining signatures could eventually lead to further stratification of 
patients with different survival properties and can aid in the selection of specific 
patient groups for therapies directed at these various processes. Previous studies 
have shown that combining the Wound signature56 with either the 70-gene 
signature6, a hypoxia signature48 or the invasiveness gene signature (IGS)11 resulted 
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in the definition of three subclasses of patients with distinct differences in survival 
leading to improved prognostic performance compared to single marker 
performance11,57,58. 
Gene expression signatures in the clinic 
A possible limitation to the application of gene expression-based classifiers is the 
intra-tumor heterogeneity of tumors. In general most of the gene expression 
microarray studies are performed on surgically treated patients and whole tumor 
tissues are available for profiling. In order to optimally apply these markers for 
patient treatment decisions it will be essential to know whether transcriptomic 
information on the whole tumor can be captured from biopsy material. This would 
allow information to be obtained at the diagnostic stage rather than during 
treatment, and thus to inform a larger fraction of patient care. In addition, impact 
on decision making in cancer treatment will be largest when non-surgically treated 
patients (i.e. those treated with radiotherapy alone) are also eligible for evaluation 
with these signatures. 
The same issue manifested with the emergence of tissue microarray (TMA) 
technology for immunohistochemical assessment of biomarkers. Since then 
multiple studies were performed to assess the number of core-biopsies needed to 
obtain a representative view of a single tumor59-63. Now it is widely accepted that 
two to four samples from different tumor regions suffice to get a reliable estimation 
of the information in the whole specimen64. However a recent study indicates that 
the number of tissue samples should be determined per individual biomarker for 
TMA evaluation65. Similar studies should be performed to address this issue for 
gene expression data. 
Validation in gene expression microarray research is not 
straightforward 
Although clinical application of gene expression microarray technology is widely 
expected to introduce a new chapter in personalizing cancer treatment, progress 
has been slow. As indicated before skepticism regarding gene expression-based 
signatures has been growing since reports on failed re-analyses, disappointing 
validation results and lack of consistency started to appear13,15,16,66,67. Both the high-
dimensionality of the microarray data and the numerous methods available to 
process the data play an important role. 
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Multiple testing: the problem of high-dimensionality data 
A large part of these negative results can be attributed to the fact that in microarray 
research we deal with high-dimensionality data coupled to insufficient statistical 
power. This problem is often referred to as ‘the curse of dimensionality’: the 
expression of (tens of) thousands of genes (independent variables) are 
simultaneously measured whereas the number of samples (dependent variables) is 
limited to maybe a few hundred. Without the use of proper statistical and 
computational methods to account for this difference in dimensionality there is a 
major risk of over-fitting, which can lead to the reporting of overoptimistic 
results13,14,68. 
When identifying genes differentially expressed between two patient groups 
traditional statistical methods such as the two-sample t-test will be challenged with 
serious multiplicity69,70. For example, when taking a microarray with 25,000 genes 
and a standard measure for significance (p < 0.05) one will expect around 1,250 
false discoveries. Various alternative methods have been suggested to better deal 
with this type of high-dimensionality data for gene selection71. Series of adjusted 
statistics, like Bonferroni adjustment72 and Benjamini and Hochberg correction73, 
resampling techniques74,75 and dimensionality reduction methods76,77, like principle 
component analysis (PCA)78 and support vector machines (SVM)79, have been 
introduced to control the level of false discoveries and elucidate the truly 
differentially expressed genes, which resulted in improved marker performance in 
validation data. 
Influence of multiplicity in signature testing 
Despite all statistically-based efforts to account for multiple testing, it is crucial to 
validate prognostic gene expression-based markers in independent data. Studied 
patient cohorts are merely small subsets of the total patient population of interest 
and are usually assembled at a single site. The diversity observed in the studied 
cohort is not representative of the variety in the total patient population for a 
number of reasons including differences in experimental procedure (RNA 
extraction, array batch effects) and epidemiological factors. On top of that, 
classification is often more relevant in a subgroup of the studied cohort, however 
subgroup analyses are largely underpowered owing to the small numbers of 
patients included. In addition the process of marker identification almost always 
includes a training step, true value of the created classifier can then only be 
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assessed by testing the marker in independent data. Prognostic power is 
determined with traditional survival statistics. Although only one or a few markers 
are typically validated, we show in chapter 5 that one has to deal with multiple 
testing problems at the signature testing phase. We propose a method to obtain an 
estimate of the performance of the signature in a specific dataset relative to an 
empirically-determined null distribution. We develop techniques to estimate this 
null distribution by evaluating randomly-generated gene signatures, and use these 
to confirm previous findings that the number of included samples dramatically 
affects the false discoveries showing the importance of large cohorts68,80,81. Large 
differences in the performance of random gene sets were identified between 
datasets. Boutros et al82 recently used a similar permutation-based approach to 
evaluate their signature in multiple datasets. 
In addition we show that once the number of validation datasets increases the 
multiple testing issue plays a smaller part (chapter 5). At the moment most 
published signatures are validated in a small number of datasets. Worse, for certain 
tumor types or specific treatments, for example patients treated with a new drug, 
the number of validation cohorts can be limited. Our new technique could 
strengthen the findings in these statistically-challenging but medically-critical cases, 
by adding an additional measure of classifier performance which accounts for the 
high data dimensionality. 
Data Sensitivity to pre-processing 
One of the other issues leading to inconsistent results and discrepancies in 
signature gene content is the large variety of microarray technologies, pre-
processing methods and analysis techniques available in the field of gene 
expression microarray analyses70. Initially, reports on inter-platform and cross-
laboratory studies showed poor repeatability, reproducibility and comparability of 
microarray technology83-86. More recently, modern arrays and improved statistical 
methods have led to more concordant results: several studies show reasonable to 
good agreement of microarray data generated using different platforms or at 
different sites87-89. Nevertheless, when Ioannidis et al66 tried to replicate data 
analyses from a series of published gene expression microarray studies, only a few 
analyses could be reproduced. This could mainly be attributed to the unavailability 
or incompleteness of available data and lack of reporting of analysis details. More 
transparent analyses descriptions and better data accessibility will thus lead to 
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increased data repeatability and will make evaluation of developed models by 
independent groups easier. 
To systematically address issues regarding intra- and inter-platform reproducibility, 
the MicroArray Quality Control (MAQC) consortium, comprised of more than 50 
organizations and 130 scientists, was established. In their first series of publications, 
consistent agreement was reported both for gene expression data from the same 
platform at different test sites and across data generated by different 
technologies90-95. In a large multi-site follow-up study, the group changed their 
focus from the technical aspects of gene expression microarray technology to the 
data analysis methods96. Six datasets with different endpoints were analyzed by 36 
independent teams to extract classification models. In total more than 30,000 
models were generated using a wide variety of analytical methods. Overall models 
generated with different methods showed high agreement in performance. This 
confirms previous data from individual research groups demonstrating that the 
application of different algorithms yielded similar classifications12,17,82,97. The studied 
endpoint and team competence largely influence model performance. They further 
emphasize the importance of applying the same processing pipeline to validation 
datasets as was used for the training datasets. 
Studies evaluating different pre-processing schedules have shown that the use of 
different schemes greatly influence downstream analyses, which for example can 
result in completely different identified gene lists98-100. Coombes et al15 and Baggerly 
et al16 demonstrated that the use of different pre-processing resulted in failed 
reproduction of drug sensitivity predictions. These data could imply that diverging 
from the scheme used in an original report might lead to failed validation in 
subsequent studies and unnecessary negative conclusions on gene expression 
microarray technology. We systematically studied the influence of different pre-
processing schedules on the performance of a previously published 3-gene lung 
cancer marker101 in a large independent microarray dataset46 (chapter 7). When the 
prescribed pre-processing methodology was applied, the 3-gene marker successfully 
validated in this new cohort. However we show that minor alterations in pre-
processing could change a successful biomarker into one indistinguishable from 
random chance. In a recent review, Subramanian and Simon67 failed to validate two 
lung cancer signatures including the 3-gene marker in the same independent 
dataset and concluded that any of the NSCLC signatures available at the moment 
are ready for clinical application. We identified substantial differences in the 
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adopted pre-processing schedule used by Subramanian and Simon67 compared to 
the one reported in the original study (chapter 6) and identify this as the cause of 
failed validation (chapter 7). The use of different pre-processing schedules resulted 
in changed classification status of a significant portion of patients (chapter 7). For 
now marker validation should follow a consistent pre-processing scheme. However, 
we hypothesize that this data pre-processing sensitivity can be used to improve 
biomarker robustness on a per-patient basis. 
Standardizing the gene expression profiling pipeline for a specific marker, continued 
validation in new datasets and transparent descriptions of data analyses schedules 
will result in better gene expression-based markers and more rapid integration in 
clinical settings. 
Future perspectives 
Accelerating clinical utility of high-throughput gene expression 
profiling 
The first mRNA-based classifiers are currently being tested in large clinical 
prospective trials102-104. As a result, the use of microarrays for high-throughput 
gene-expression profiling shows significant potential for predicting both prognosis 
and response to therapy. Since the introduction of microarray-based technology, 
many efforts have been made to revise study design, pre-processing and analysis 
methodology to improve clinical utility105. Continued advances in computational and 
experimental approaches will make it increasingly practical to translate microarray 
studies to patient settings. 
One important issue that remains to be addressed is that most markers are 
evaluated in a relative fashion. The earliest gene expression microarray studies used 
a subset of genes to cluster patients in different groups5,106,107. This approach has 
several disadvantages, for example unsupervised clustering could be unstable in the 
presence of outliers, and the employment of a different algorithm might result in 
completely different patient groups, making this a subjective analysis strategy108. 
Recent studies have therefore moved towards more quantitative evaluations, like 
assigning scores derived from expression of each genes in the classifier. However in 
most cases these scores are used to arbitrarily group patients, for example by 
dichotomizing the median score within a population. Converting these markers to 
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absolute measures to provide rigorous estimates of patient risk, and the 
establishment of the associated classification thresholds and cut-off values will be 
essential for introduction into patient decision making. 
Another important requirement for the success of future studies is complete data 
and analysis procedure reporting66,67,105. Transparent reporting of computational 
approaches makes it easier for external parties to evaluate published gene 
signatures in their own datasets. In addition availability of more raw datasets will 
increase the amount of data that can be used for validation purposes. These will 
lead to an increase in the rate at which a classifier will be accepted, and may indeed 
increasingly become a requirement for approval by governments and insurance 
companies. 
Next-generation sequencing (NGS) technology 
Gene expression profiling accounts for the majority of publications on markers 
identified with high throughput technologies. However, recent advances in next-
generation sequencing (NGS) have enormously decreased the costs of high-
throughput sequencing, making this technique practical for large cohorts for the 
first time109. Transcriptome or exome NGS will eventually overtake application of 
gene expression microarrays for several reasons. First of all NGS provides exquisite 
sensitivity and resolution far beyond that of other high-throughput 
technologies110,111. Second, exome and transcriptome NGS provides much more 
information than microarrays112. Data can also be used to identify gene fusions113, 
alternative splicing variants114 and possibly different types of mutations115. Third, 
analyses are not limited to the transcripts available on a gene chip, but can also 
detect novel transcripts116,117. Thus with the emergency of affordable NGS, 
enormous datasets will become available and the analyses of these data will 
become a key and challenging task109,118. Tools to analyze this type of data have 
started to emerge but, are currently very limited in scope and validation119. 
The increased accessibility of NGS data further provides the possibility to study 
much more than only the transcriptome120. Whole genome sequencing will 
generate a complete spectrum of the mutations, amplifications and silencing 
present in a tumor sample112. For this type of NGS it will be most important to 
identify what genetic alterations are driving tumorigenesis and tumor progression 
and which ones are secondary or passenger variations109. Targeted NGS, like 
chromosome immune-precipitation (ChiP) followed by high-throughput sequencing 
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procures data on the epigenome, like DNA methylation or histone acetylation, and 
DNA-protein interactions121. Combining different NGS types will in the end 
dramatically expand our understanding of cancer as a disease and ultimately result 
in better diagnostics, new and improved targeted treatments and increased 
survival.  
The need for multi-factorial decision tools 
Due to the complexity of tumor biology it is likely that only the employment of 
multi-factorial markers will lead to truly individualized therapy decisions. To 
understand complex cancer biology it will be key to elucidate the molecular events 
at different levels like genomics, transcriptomics and proteomics and to combine 
these into a unified model of the effects and implications on functional molecular 
pathway and treatment outcome. Ultimately information from multiple modalities 
like patient characteristics, clinical and staging data, molecular markers, imaging 
data and treatment information will be integrated in decision support systems 
(DSSs) to optimize treatment for each individual patient. 
We are still far from realizing such extensive DSSs to integrate high-throughput data 
with clinical and imaging parameters. Most studies so far focus on the use of a 
single modality to define novel molecular prognosticators; follow-up studies are 
needed to address whether these markers in combination with other parameters 
really increase clinical utility. 
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Summary 
One of the major focuses in cancer research is the identification of novel biomarkers 
and therapeutic targets to improve treatment outcomes. There is a significant need 
to enhance both the accuracy and precision of risk prediction and therapy selection. 
Advances in both molecular and clinical cancer research have improved prognosis 
and reduced side-effects. Nonetheless, available therapy remains ineffective in a 
large fraction of patients. New biomarkers could help predict which patients would 
benefit from a treatment. 
With the advent of high-throughput technologies it became possible to study 
enormous numbers of parameters simultaneously, opening up a new era of 
possibilities to identify novel markers much faster than previously possible. 
One of these novel technologies, gene-expression microarrays have been widely 
used in cancer research for the last decade. Measuring the expression of thousands 
of genes in parallel has the potential to answer many questions that were 
previously impossible to resolve. This type of transcriptomic profiling has, amongst 
others, led to the identification of dysregulated pathways in cancer. Furthermore, 
multi-gene markers (so-called gene signatures) have been created that show the 
promise to improve risk prediction and therapy selection. Despite progress in this 
area, introduction into clinical practice has been slow. Only two breast cancer gene 
signatures are currently tested in clinical trials. Reports on minimal gene-wise 
overlap, disappointing validation in external data and lack of consistency have 
negatively impacted the field. 
The first part of this thesis focuses on the creation of a robust, biology-bases gene 
signature for multiple cancer types. In the second part of this thesis we elaborate on 
the data analysis of microarray experiments. 
Proliferation signature 
Recently it has been reported that, although gene-wise overlap is poor, 
classification results from different signatures show high agreement. It is thought 
that this phenomenon reflects common underlying biology represented by each 
classifier in a different way. In breast cancer, more and more data suggests that 
cellular proliferation plays a major role in the prognosticity of gene signatures. 
To clarify the significance of proliferation in prognostic breast cancer signatures we 
created a gene expression-based marker reflecting cellular proliferation (chapter 2). 
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Two in vitro gene expression datasets were combined to extract this signature: 
genes were selected that showed a cycling expression pattern after synchronization 
in one dataset and responded to serum stimulation in the other. This 104-gene 
proliferation signature had high prognostic power in different breast cancer 
datasets. We further hypothesized that this marker could also be used for 
prognostic purposes in other cancer sites and validated it across multiple cancer 
types. A further independent validation of our proliferation signature was 
performed by relating gene expression to other proliferation measures in both 
patient and xenograft material (chapter 3). 
Since the clinical utility of microarrays can be controversial, we sought to evaluate 
our classifier using an independent technique. In chapter 4 the number of genes in 
the signature was computationally-reduced in an information-preserving manner, 
followed by experimental evaluation using RT-PCR. This reduced marker was 
successfully tested in two large patient microarray meta-datasets. Subsequently, 
this refined marker was validated with PCR in vitro, in vivo and in an independent 
primary breast cancer cohort. 
Challenges in microarray data analysis 
Several aspects of high-throughput gene expression profiling involve major 
technical challenges. The first lies in the dimensionality of a microarray experiment, 
where thousands of genes are simultaneously measured in a relatively small 
number of samples. Without the use of proper statistical and computational 
methods to account for this “curse of dimensionality” there is a major risk of over-
fitting, which can lead to the reporting of over-optimistic and non-generalizable 
results. Increasingly sophisticated methods are being developed to handle this 
problem when identifying interesting genes and signatures from microarray data. 
This has clearly led to an improvement in quality of the reported classifiers. Less 
notice of the multiple testing issue is taken once a signature is created.  
Nevertheless, despite all efforts to account for multiple testing and over-fitting, it is 
crucial to independently validate prognostic gene expression-based. At this stage 
standard survival statistics are generally used to address prognosticity. 
In chapter 5 we clearly shown that also in this phase great care must be taken. By 
testing sets of randomly-generated signatures in multiple independent datasets we 
demonstrate that many gene sets reach statistical significance. In some datasets the 
proportion of significant gene-sets reached dramatic levels, indicating that a single, 
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dataset-invariant threshold for significance is inappropriate. Based on this 
permutation study, we suggest a method to test signature performance to control 
for spurious random findings. In addition, our data demonstrates that evaluating a 
signature in multiple independent datasets attenuates the multiple testing issue. 
Another reason for discrepancies and inconsistencies in reported studies is the 
enormous diversity of available microarray platforms and pre-processing 
techniques. Variations in either of these parameters can result in identification of 
different genes and signatures. Many previously reported failed data replications 
can be attributed to unavailability or incompleteness of data or analysis details. 
We therefore believe it is essential to follow the original data handling pipeline as 
precisely as possible (chapter 6), as failure to do so may in part explain why 
independent validation of signatures by other research groups often fails. Although 
in most of the cases the statistical methods are properly followed, far less attention 
is usually paid to data pre-processing. We sought to clarify the importance of 
standardizing the pre-processing schedule for gene expression-based classifiers. 
Two existing non-small-cell lung cancer signatures were tested in an independent 
dataset pre-processed with 24 different methods. The data in chapter 7 clearly 
demonstrates that even small changes in pre-processing could change a successful 
marker into one indistinguishable from chance. 
Our results do not only reveal the sensitivity of marker performance to the applied 
pre-processing, but also lead to the report of a new validation of two non-small-cell 
lung cancer markers in a new, large patient cohort. Interestingly, this study revealed 
that when focusing on those patients for whom different pre-processing schemes 
agree prognostic capability increased. This feature might be exploited to improve 
classifier robustness. 
 
In conclusion, we created a signature for cellular proliferation, which demonstrated 
high prognostic power in multiple cancer types. We successfully translated this 
marker to a PCR-based classifier, which will increase clinical utility. In the second 
part of the thesis we identify several key issues that when kept in mind will improve 
reported classifier validity. Two novel methods for assessing signature robustness 
were developed. Taken together, these results make concrete and practical steps 
towards speeding the integration of molecular diagnostics with clinical practice. 
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Samenvatting 
Het identificeren van nieuwe biomarkers en het stellen van therapeutische doelen 
ter verbetering van de behandeling is een van de speerpunten van 
kankeronderzoek. Het is duidelijk dat er nauwkeurigere methoden voor het 
voorspellen van het behandelingsresultaat en het bepalen van de optimale 
behandeling per individu nodig zijn. Vooruitgang op het gebied van onderzoek en 
verbetering van de bestaande behandelmethodes hebben zeer zeker een positief 
effect gehad op de prognose van patiënten.  Echter, voor een groot deel van de 
patiënten blijven beschikbare therapieën inefficiënt of zelfs onbeduidend. 
Met de opkomst van ‘high-throughput’ technieken is het mogelijk geworden om 
een zeer groot aantal parameters tegelijkertijd te bestuderen. Door deze 
ontwikkeling kunnen nieuwe markers vele malen sneller worden geïdentificeerd 
dan voorheen mogelijk was. 
Een van deze nieuwe methoden, genaamd gen-expressie microarray technologie, 
wordt reeds veelvuldig gebruikt binnen het kankeronderzoek. Met deze techniek 
kan de expressie van duizenden genen tegelijkertijd worden gemeten, waardoor het 
mogelijk is om vele vraagstukken te ontrafelen die voorheen onmogelijk te 
beantwoorden waren. Er zijn sinds de introductie van deze methode verscheidene 
biologische processen gevonden die ontregeld zijn binnen kankercellen. Daarnaast 
worden gen-expressie microarrays veelvuldig gebruikt om multi-gen markers te 
genereren. Een zodanig samengestelde set genen heeft de potentie om te 
voorspellen welke patiënten goed op een behandeling zullen reageren en welke een 
slechtere prognose hebben. Het idee is dat deze markers uiteindelijk zullen 
bijdragen aan het bepalen van de meest optimale behandeling voor een patiënt.   
Ondanks de voortgang in onderzoek op dit gebied verloopt de introductie van gen-
expressie microarrays en geïdentificeerde multi-gen markers in een klinische setting 
traag. Momenteel zijn er slechts twee grote klinische studies gestart waarin multi-
gen markers voor borstkanker worden getest. Rapportage van minimale gen overlap 
tussen markers, teleurstellende validatie resultaten in externe data en een gebrek 
aan consistentie dragen hiertoe bij. 
 
Het eerste gedeelte van deze thesis behandelt de ontwikkeling van een robuuste 
multi-gen marker die mogelijk voor meerdere kankersoorten kan worden toegepast. 
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In het tweede deel wordt dieper ingegaan op de analyse van gen-expressie 
microarray data en wat de invloed hiervan is op marker resultaten.  
Multi-gen marker voor proliferatie 
Uit recent onderzoek blijkt ondanks dat er een gebrek aan overlap tussen multi-gen 
markers is, dat de patiënt classificaties met deze markers zeer goed 
overeenstemmen. Er wordt gedacht dat ongeacht of deze multi-gen markers qua 
inhoud verschillen of niet, ze gelijkwaardige biologie representeren. Verder wijst 
steeds meer onderzoek naar borstkanker erop dat proliferatie een belangrijke rol 
speelt ten aanzien van de prognostische waarde van multi-gen markers.  
Om deze redenen hebben we in hoofdstuk 2 een multi-gen marker ontwikkeld voor 
proliferatie. Onze verwachting is dat deze marker niet alleen van prognostische 
waarde zal zijn voor borstkanker patiënten, maar ook toepasbaar zal zijn voor 
andere kankersoorten. Om deze set van genen te creëren is informatie uit twee in 
vitro microarray datasets gecombineerd. In totaal werden 104 genen geselecteerd 
die een cyclisch expressie patroon volgden na synchronisatie in de ene dataset en 
een reactie vertoonden op stimulatie met serum in een andere dataset. Deze multi-
gen proliferatie marker heeft een hoge prognostische waarde in verschillende 
patiënten microarray datasets. Een tweede validatie werd uitgevoerd door 
expressie van de proliferatie-geassocieerde genen te correleren aan andere 
metingen van proliferatie materiaal van patiënten en xenografts (hoofdstuk 3). 
 Aangezien de introductie van microarrays in een klinische setting nog moeilijk 
verloopt, hebben we gezocht naar een alternatieve methode om de proliferatie 
marker te bekijken. In hoofdstuk 4 hebben we het aantal genen in de multi-gen 
marker verkleind, zodat het mogelijk werd om deze te evalueren met een 
onafhankelijke techniek: PCR. De prognostische waarde van deze nieuwe marker 
werd succesvol getest in twee grote microarray meta-datasets van patiënten. 
Daaropvolgend werd de aangepaste marker in vitro, in vivo en in een onafhankelijke 
patiënten dataset gevalideerd met PCR. 
Microarray data analyse 
Verschillende aspecten van ‘high-throughput’ methodes gaan gepaard met 
aanzienlijke technische vereisten. De dimensionaliteit van microarray data, waarbij 
expressie van duizenden genen tegelijkertijd wordt gemeten in een relatief klein 
aantal monsters, brengt een aantal uitdagingen met zich mee wat betreft de data-
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analyse. Zonder het gebruik van geschikte statistische methoden en computer 
algoritmes bestaat er een groot risico van over-fitting, dat kan leiden tot rapportage 
van over-optimistische resultaten. Er worden steeds meer geavanceerde 
procedures ontwikkeld om hiervoor te corrigeren tijdens het identificeren van 
interessante genen en het afleiden van multi-gen markers. Dit heeft zeker effect 
gehad op de kwaliteit van gegenereerde markers. Er wordt minder aandacht 
besteed aan dit probleem nadat een nieuwe marker is gecreërd, het is echter 
essentieel om prognostische gen-expressie gebaseerde markers te valideren op 
onafhankelijke data. Om de prognostische waarde van deze markers te bepalen 
worden meestal standaard methodes voor overlevings statistiek toegepast. 
In hoofdstuk 5 tonen we aan dat ook in dit stadium rekening gehouden moet 
worden met de dimensionaliteit van de data. Door het genereren en testen van 
random multi-gen markers, werd duidelijk dat een groot aantal van deze 
willekeurige markers statistisch significante resultaten opleverden. Afhankelijk van 
de dataset bereikte dit aantal een dramatisch hoog niveau, waardoor het gebruik 
van een enkele drempel voor significantie niet geschikt is voor dit soort analyses. 
Om te controleren voor random bevindingen stellen we een methode voor om 
multi-gen markers te evalueren gebaseerd op deze permutatie studie. Daarnaast 
wijst de data in deze studie erop dat bij het testen van een marker in meerdere 
onafhankelijke datasets het van minder groot belang is om hier rekening mee te 
houden. 
 
Een andere reden voor gerapporteerde tegenstrijdigheden en instabiliteit van multi-
gen markers is het grote scala aan beschikbare microarray types, data 
voorbewerkingstechnieken en analyse methoden. Veranderingen in een van deze 
parameters resulteert in de identificatie van andere genen en dus ook in 
uiteenlopende multi-gen markers. Eerdere beschrijvingen over mislukte data 
replicatie konden meestal worden toegeschreven aan onvolledige of niet 
beschikbare ruwe data of analyse details. 
Voor externe validatie denken we dat het essentieel is om de data bewerking zo 
precies mogelijk te volgen als omschreven in de oorspronkelijke studie (hoofdstuk 
6). Onafhankelijke validatie van multi-gen markers geïdentificeerd door andere 
onderzoeksgroepen leveren doorgaans negatieve resultaten op. Hoewel in de 
meeste gevallen de analyse methoden tot in detail worden gevolgd, wordt er veel 
minder aandacht besteedt aan de data voorbewerking. Om het belang van 
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standaardisering van data voorbewerking te verduidelijken, werden twee bestaande 
multi-gen markers voor niet-kleincellig long carcinoma getest in een onafhankelijke 
dataset die met 24 verschillende schema’s werd voorbewerkt. Uit de data in 
hoofdstuk 7 blijkt dat zelfs kleine aanpassingen in een voorbewerkings schema een 
succesvolle marker kunnen veranderen in een marker die niet te onderscheiden is 
van toeval. 
In dit hoofdstuk laten we zien dat de prognostische waarde van een marker zeer 
gevoelig is voor de gebruikte voorbewerkings techniek. Ook valideren we twee 
multi-gen markers voor niet-kleincellig long carcinoma in een nieuwe, grote dataset. 
Een andere interessante bevinding van deze studie is dat wanneer alleen patiënten 
in acht worden genomen waarvoor de verscheidene voorbewerkingen een gelijke 
classificatie geven, de prognostische waarde sterk toeneemt. Deze eigenschap zou 
in de toekomst gebruikt kunnen worden om marker robuustheid te verbeteren. 
 
Concluderend, omschrijven we in deze thesis de ontwikkeling van een muti-gen 
marker voor proliferatie, die een hoge prognostische waarde heeft in meerdere 
kankertypes. Deze marker werd succesvol omgezet in een PCR-gebaseerde marker, 
waardoor de toepasbaarheid in een klinische setting vergemakkelijkt zal worden. In 
het tweede deel van deze thesis identificeren we een aantal belangrijke punten 
waar rekening mee gehouden dient te worden bij de analyse van microarray data. 
Twee nieuwe methoden werden ontwikkeld om de robuustheid van een marker te 
bepalen. Dit zal bijdragen aan het verbeteren van de kwaliteit van multi-gen 
markers en leiden tot een snellere vertaling naar de kliniek. 
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